Epidermolysis Bullosa Simplex

Mendelian MONDO:0017610 Pathograph 7 Dermatological Disease Genetic Disease

Epidermolysis bullosa simplex (EBS) is the most common form of EB, characterized by intraepidermal blistering within the basal cell layer. Most cases are caused by dominant-negative mutations in KRT5 or KRT14 encoding keratins 5 and 14 in basal keratinocytes. Blisters generally heal without significant scarring. Subtypes range from localized palmoplantar blistering to severe generalized forms with herpetiform blistering, and include EBS with muscular dystrophy caused by PLEC mutations.

Ask OpenScientist

Ask a research question about Epidermolysis Bullosa Simplex. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Mappings
0
Definitions
2
Inheritance
5
Pathophysiology
0
Histopathology
7
Phenotypes
7
Pathograph
6
Genes
8
Treatments
5
Subtypes
0
Differentials
1
Datasets
2
Trials
0
Models
12
References
1
Deep Research
🏷

Classifications

Harrison's Chapter
skin disorder hereditary disease
🔗

Mappings

MONDO
MONDO:0017610 epidermolysis bullosa simplex
skos:exactMatch MONDO
Primary MONDO disease identifier for this EBS entry.
ICD-10-CM
ICD10CM:Q81.0 Epidermolysis bullosa simplex
skos:exactMatch ICD-10-CM
ICD-10-CM Q81.0 directly names epidermolysis bullosa simplex.
👪

Inheritance

2
Autosomal dominant
Most EBS subtypes (localized, intermediate, severe/Dowling-Meara) are inherited in an autosomal dominant manner due to dominant-negative keratin mutations in KRT5 or KRT14.
Show evidence (2 references)
PMID:20301543 SUPPORT Human Clinical
"The diagnosis of EBS is established in a proband by: the identification of a heterozygous dominant-negative variant or biallelic loss-of-function variants in KRT5, KRT14, or PLEC"
GeneReviews confirms dominant-negative variants in KRT5/KRT14 as a major cause of EBS.
PMID:16098032 SUPPORT Human Clinical
"18 were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively"
Confirms heterozygous (dominant) keratin mutations as a cause of EBS.
Autosomal recessive
EBS with muscular dystrophy (PLEC mutations) and EBS autosomal recessive (KRT14 null) are inherited in an autosomal recessive manner.
Show evidence (2 references)
PMID:34572129 SUPPORT Human Clinical
"The most common disorder is autosomal recessive disease epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), which is characterized by skin blistering and progressive muscle weakness"
Confirms autosomal recessive inheritance of EBS-MD caused by PLEC mutations.
PMID:25530118 SUPPORT Human Clinical
"Plectin deficiency causes autosomal recessive epidermolysis bullosa simplex (EBS) with involvement of the skin and other organs"
Confirms autosomal recessive inheritance pattern for plectin-related EBS.
◆

Subtypes

5
EBS Localized (formerly Weber-Cockayne)
Blistering mainly confined to hands and feet, exacerbated by heat and increased physical activity. The mildest and most common form of EBS. Onset typically in infancy or early childhood.
EBS Intermediate (formerly Koebner)
Generalized non-scarring blistering that may affect any body site. More widespread than localized EBS but less severe than the severe form. Blisters heal without significant scarring.
EBS Severe (formerly Dowling-Meara)
Grouped herpetiform blistering, palmoplantar keratoderma, and nail dystrophy. The most severe keratin-associated form of EBS. Blistering tends to improve with age, likely due to the suprabasal switch from K5/K14 to K1/K10 during keratinocyte differentiation reducing dependence on mutant basal keratins. Improvement with age is common in all variants of EBS but is not invariable. The pathognomonic transmission electron microscopy (TEM) finding is tonofilament (keratin) clumping in basal cells. Laryngeal involvement may occur.
EBS with Muscular Dystrophy
Caused by PLEC mutations leading to skin fragility combined with progressive muscular dystrophy. Autosomal recessive inheritance. Plectin deficiency disrupts both epidermal and muscle cytoskeletal integrity.
EBS Autosomal Recessive (KRT14 null)
Severe, generalized blistering caused by biallelic loss-of-function mutations in KRT14 resulting in complete absence of keratin 14 protein. More severe than typical dominant EBS.
⚙

Pathophysiology

5
KRT5/KRT14 Mutations Disrupt Keratin Intermediate Filament Network
Mutations in KRT5 or KRT14 genes disrupt the keratin intermediate filament network in basal keratinocytes of the epidermis. Keratins 5 and 14 are the obligate type II and type I intermediate filament partners that copolymerize to form the 10 nm filament network providing mechanical resilience to basal keratinocytes.
epidermal cell link
KRT5 link KRT14 link
intermediate filament organization link ⚠ ABNORMAL
Downstream
Dominant-Negative Disruption of Filament Assembly Mutant keratins poison the filament network by incorporating into filaments and destabilizing them.
Show evidence (2 references)
PMID:22277943 SUPPORT Human Clinical
"Most cases of EBS are due to dominantly acting mutations in keratin 14 (K14) or K5, the type I and II intermediate filament (IF) proteins that copolymerize to form a pancytoplasmic network of 10 nm filaments in basal keratinocytes of epidermis and related epithelia"
Confirms K5/K14 as the obligate IF pair in basal keratinocytes and dominant mutations as the cause of EBS.
PMID:30078200 SUPPORT Human Clinical
"the most important and most commonly occurring molecular defects in these patients are the defects of keratins 5 and14 (KRT5 and KRT14)"
Confirms KRT5 and KRT14 defects as the primary molecular basis of EBS.
Dominant-Negative Disruption of Filament Assembly
Mutant keratins exert a dominant-negative effect by incorporating into keratin filaments and poisoning the entire filament network. This disrupts filament architecture and leads to keratin aggregate formation, particularly under conditions of mechanical or thermal stress.
epidermal cell link
intermediate filament cytoskeleton organization link ⚠ ABNORMAL
Downstream
Mechanical Stress-Induced Keratinocyte Cytolysis Disrupted keratin network renders basal keratinocytes fragile and prone to rupture under mechanical stress.
Show evidence (2 references)
PMID:22277943 SUPPORT Human Clinical
"Defects in K5-K14 filament network architecture cause basal keratinocytes to become fragile, and account for their rupture upon exposure to mechanical trauma"
Confirms that disrupted keratin filament architecture causes basal keratinocyte fragility and rupture.
PMID:34830328 SUPPORT In Vitro
"Keratin aggregates display impaired dynamics of assembly and diminished solubility and appear to be the trigger for endoplasmic reticulum (ER) stress upon being phosphorylated by MAPKs"
Confirms that mutant keratins form aggregates with impaired dynamics, triggering downstream ER stress signaling.
Mechanical Stress-Induced Keratinocyte Cytolysis
Basal keratinocytes with disrupted keratin networks rupture (cytolyse) when subjected to mechanical trauma. The blistering in EBS is intraepidermal, occurring within the basal cell layer rather than at tissue interfaces, distinguishing it from junctional and dystrophic EB.
epidermal cell link
cell death link ↑ INCREASED
Show evidence (2 references)
PMID:16098032 SUPPORT Human Clinical
"Epidermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blistering within the basal keratinocytes as a result of trauma to the skin"
Confirms intraepidermal blistering within basal keratinocytes as the hallmark of EBS.
PMID:34830328 SUPPORT In Vitro
"Epidermolysis bullosa simplex (EBS) is a group of inherited keratinopathies that, in most cases, arise due to mutations in keratins and lead to intraepidermal ruptures"
Confirms that keratin mutations lead to intraepidermal rupture.
PLEC Mutations Disrupt Hemidesmosome-Cytoskeleton Linkage
Mutations in PLEC disrupt plectin, a giant cytoskeletal crosslinker that connects the keratin intermediate filament network to hemidesmosomes at the dermal-epidermal junction and to the desmin cytoskeleton in muscle. Loss of plectin causes a dual phenotype affecting both skin (blistering) and skeletal muscle (progressive dystrophy).
epidermal cell link skeletal muscle fiber link
PLEC link
cell-substrate junction organization link ⚠ ABNORMAL
Downstream
Mechanical Stress-Induced Keratinocyte Cytolysis Disrupted hemidesmosome-cytoskeleton linkage leads to skin fragility.
Show evidence (2 references)
PMID:34572129 SUPPORT Human Clinical
"Plectin is a giant cytoskeletal crosslinker and intermediate filament stabilizing protein. Mutations in the human plectin gene (PLEC) cause several rare diseases that are grouped under the term plectinopathies"
Confirms plectin as a cytoskeletal crosslinker whose mutations cause plectinopathies including EBS-MD.
PMID:25530118 SUPPORT Human Clinical
"Plectin deficiency causes autosomal recessive epidermolysis bullosa simplex (EBS) with involvement of the skin and other organs, such as muscle and gastrointestinal tract, depending on the expression pattern of the defective protein"
Confirms plectin deficiency causes EBS with multi-organ involvement including skin and muscle.
Heat Sensitivity of Mutant Keratin Networks
Mutant keratin filament networks are thermally unstable. Elevated temperature causes filament breakdown into aggregates, explaining the clinical observation that blistering worsens in warm weather and with increased perspiration. This is particularly prominent in localized EBS.
response to heat link ⚠ ABNORMAL
Show evidence (1 reference)
PMID:8586658 SUPPORT In Vitro
"after thermal stress a reduced stability of the keratin filaments was demonstrable in the epidermolysis bullosa simplex cell lines, with filaments breaking into aggregates"
Demonstrates that thermal stress causes keratin filament breakdown into aggregates in EBS cell lines, explaining heat-exacerbated blistering.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Epidermolysis Bullosa Simplex Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Integument 6
Skin Blistering OCCASIONAL Abnormal blistering of the skin (HP:0008066)
Show evidence (2 references)
PMID:20301543 SUPPORT Human Clinical
"Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma"
GeneReviews confirms non-scarring blisters from minor mechanical trauma as the hallmark of EBS.
PMID:32973163 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible by often minimal trauma"
Nature Reviews Disease Primers confirms blister formation from minimal trauma as the defining feature of EB.
Heat-Exacerbated Blistering VERY_FREQUENT Abnormal blistering of the skin (HP:0008066)
Show evidence (1 reference)
PMID:8586658 SUPPORT In Vitro
"after thermal stress a reduced stability of the keratin filaments was demonstrable in the epidermolysis bullosa simplex cell lines, with filaments breaking into aggregates"
Demonstrates thermal instability of mutant keratin filaments, providing the molecular basis for heat-exacerbated blistering.
Palmoplantar Keratoderma FREQUENT Palmoplantar keratoderma (HP:0000982)
Primarily seen in EBS severe (Dowling-Meara)
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation"
GeneReviews confirms palmoplantar keratoderma as an additional feature of EBS.
Herpetiform Blistering Pattern FREQUENT Abnormal blistering of the skin (HP:0008066)
Characteristic of EBS severe (Dowling-Meara) subtype
Show evidence (1 reference)
PMID:34830328 SUPPORT In Vitro
"Mutations in keratins 5/14 or in other genes that encode associated proteins induce structural disarrangements of different strengths depending on their locations in the genes"
Confirms that mutation location determines severity of structural disarrangement, explaining the severe herpetiform phenotype in Dowling-Meara EBS.
Nail Dystrophy FREQUENT Nail dystrophy (HP:0008404)
Show evidence (1 reference)
PMID:34572129 SUPPORT Human Clinical
"PLEC mutations lead to EBS with nail dystrophy"
Confirms nail dystrophy as a recognized feature of PLEC-associated EBS.
Milia OCCASIONAL Milia (HP:0001056)
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation"
GeneReviews lists milia as an additional feature of EBS.
Musculoskeletal 1
Muscular Dystrophy OBLIGATE Muscular dystrophy (HP:0003560)
Specific to EBS with muscular dystrophy (PLEC mutations)
Show evidence (2 references)
PMID:34572129 SUPPORT Human Clinical
"The most common disorder is autosomal recessive disease epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), which is characterized by skin blistering and progressive muscle weakness"
Confirms progressive muscle weakness as a defining feature of EBS-MD.
PMID:34572129 SUPPORT Model Organism
"Skeletal muscle biopsies from EBS-MD patients and plectin-deficient mice revealed severe dystrophic features with variation in fiber size, degenerative myofibrillar changes, mitochondrial alterations, and pathological desmin-positive protein aggregates"
Confirms dystrophic muscle pathology in both human EBS-MD patients and plectin-deficient mouse models.
🧬

Genetic Associations

6
KRT5 (Causative)
Autosomal dominant
Show evidence (2 references)
PMID:16098032 SUPPORT Human Clinical
"18 were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively"
Confirms heterozygous KRT5 mutations as a cause of EBS.
PMID:30078200 SUPPORT Human Clinical
"the most important and most commonly occurring molecular defects in these patients are the defects of keratins 5 and14 (KRT5 and KRT14)"
Confirms KRT5 as one of the two principal genes mutated in EBS.
KRT14 (Causative)
Autosomal dominant Autosomal recessive
Show evidence (2 references)
PMID:22277943 SUPPORT Human Clinical
"Most cases of EBS are due to dominantly acting mutations in keratin 14 (K14) or K5"
Confirms dominant KRT14 mutations as a major cause of EBS.
PMID:16098032 SUPPORT Human Clinical
"many cases result from de novo mutations in KRT5 and KRT14 genes"
Confirms that many EBS cases arise from de novo KRT14 mutations.
PLEC (Causative)
Autosomal recessive
Show evidence (2 references)
PMID:34572129 SUPPORT Human Clinical
"Mutations in the human plectin gene (PLEC) cause several rare diseases that are grouped under the term plectinopathies"
Confirms PLEC mutations as causative for plectinopathies including EBS-MD.
PMID:16098032 SUPPORT Human Clinical
"in 14 cases, the disease was associated with mutations in both alleles of the plectin gene"
Confirms biallelic plectin mutations in EBS patients, establishing recessive inheritance.
DST (Causative)
Autosomal recessive
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"biallelic pathogenic variants in CD151, DST, or EXPH5"
GeneReviews lists DST as a gene with biallelic pathogenic variants causing autosomal recessive EBS.
EXPH5 (Causative)
Autosomal recessive
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"biallelic pathogenic variants in CD151, DST, or EXPH5"
GeneReviews lists EXPH5 as a gene with biallelic pathogenic variants causing autosomal recessive EBS.
KLHL24 (Causative)
Autosomal dominant
Show evidence (2 references)
PMID:27798626 SUPPORT Human Clinical
"We have identified start-codon mutations in the KLHL24 gene in five patients with EB."
Identifies KLHL24 start-codon mutations as a novel cause of EBS through stabilized truncated protein that excessively degrades KRT14.
PMID:27889062 SUPPORT Human Clinical
"monoallelic mutations, c.1A>G and c.2T>C, in the translation initiation codon of the gene encoding kelch-like protein 24 (KLHL24) in 14 individuals with a distinct skin-fragility phenotype and skin cleavage within basal keratinocytes"
Independently confirms KLHL24 initiation codon mutations in 14 individuals with skin fragility and basal keratinocyte cleavage.
💊

Treatments

8
Wound Care
Action: wound care Ontology label: supportive care MAXO:0000950
Supportive wound care is the mainstay of EBS management. Includes use of non-adherent dressings to protect fragile skin and promote healing of blistered areas. Blister lancing with sterile technique to prevent blister extension.
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Supportive care to protect the skin from blistering; use of dressings that will protect the skin and promote healing of wounds"
GeneReviews confirms supportive wound care as the primary management strategy for EBS.
Avoidance of Heat and Friction
Action: avoidance of triggers Ontology label: supportive care MAXO:0000950
Minimizing exposure to heat, excessive physical activity, and friction to prevent blistering episodes. Includes wearing loose-fitting clothing, soft footwear, and avoiding high ambient temperatures.
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Excessive heat exposure may exacerbate blistering and infection. Avoid poorly fitting or coarse-textured clothing/footwear and activities that traumatize the skin"
GeneReviews lists heat exposure and skin trauma as agents to avoid in EBS management.
Antiperspirants for Palmoplantar Disease
Action: topical antiperspirant therapy Ontology label: supportive care MAXO:0000950
Topical antiperspirant application to palms and soles to reduce perspiration-induced blistering, especially in localized EBS.
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Aluminum chloride (20%) applied to palms and soles can reduce sweating and therefore minimize blister formation in some individuals with EBS"
GeneReviews confirms aluminum chloride antiperspirant as a treatment to reduce sweating-induced blistering.
Pain Management
Action: pain management Ontology label: supportive care MAXO:0000950
Analgesic therapy for pain associated with blistering and erosions. May include topical and systemic pain medications depending on severity.
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"Identification and management of specific causes of pain and itching; management with a pain specialist as needed"
GeneReviews confirms pain and itch management as part of EBS care.
Physical Therapy
Action: physical therapy MAXO:0000011
Rehabilitation and physical therapy for patients with EBS-MD to maintain mobility and muscle function as muscular dystrophy progresses.
Show evidence (1 reference)
PMID:20301543 SUPPORT Human Clinical
"appropriate footwear and physical therapy to preserve ambulation"
GeneReviews confirms physical therapy to preserve ambulation as part of EBS management.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for affected families regarding inheritance patterns, recurrence risk, and prenatal diagnosis options. Important given both dominant and recessive forms and significant de novo mutation rate.
Show evidence (1 reference)
PMID:16098032 SUPPORT Human Clinical
"These findings have implications for genetic counseling and prenatal diagnosis for EBS"
Confirms the importance of genetic counseling for EBS families, particularly given de novo mutations and mixed inheritance patterns.
Diacerein (Anti-IL-1beta Therapy)
Action: diacerein anti-IL-1beta therapy Ontology label: pharmacotherapy MAXO:0000058
Topical diacerein 1% ointment, an anti-inflammatory agent that inhibits IL-1beta signaling. A phase 2/3 crossover trial (n=17) showed 86% of diacerein-treated patients achieved >40% blister reduction versus 14% with placebo. However, a larger randomized controlled trial (n=54) found no significant difference in the primary endpoint (>=60% BSA reduction at 8 weeks), though post hoc analysis in severe EBS showed a potential signal (46.2% vs 15.4% achieving optimal skin scores). Multiple ongoing trials continue to evaluate diacerein in EBS.
Show evidence (2 references)
PMID:29410318 SUPPORT Human Clinical
"Of the patients receiving diacerein, 86% in episode 1 and 37.5% in episode 2 met the primary end point (vs 14% and 17% with placebo, respectively). This effect was still significant after the follow-up"
Phase 2/3 crossover trial demonstrating diacerein efficacy in reducing EBS blisters compared to placebo.
PMID:37276163 PARTIAL Human Clinical
"Although there was no significant difference in outcomes between the groups, further study may elucidate the effects of diacerein on EBS lesions, especially in patients with severe EBS"
Larger RCT (n=54) did not meet primary endpoint overall, though post hoc analysis suggested benefit in severe EBS subgroup.
Sulforaphane (Nrf2 Activator, Preclinical)
Action: sulforaphane Nrf2 activator therapy Ontology label: pharmacotherapy MAXO:0000058
Sulforaphane, a natural product from cruciferous vegetables, activates the Nrf2 transcription factor to induce compensatory keratins K16/K17 in basal keratinocytes. In an EBS mouse model with K14 deficiency, sulforaphane treatment alleviated blistering by upregulating K17 expression. This represents an attractive preclinical approach exploiting functional redundancy within the keratin gene family.
Show evidence (1 reference)
PMID:17724334 SUPPORT Model Organism
"treatment with a pharmacological activator of Nrf2, two transcription factors eliciting distinct transcriptional programs, alleviates the blistering caused by a K14 deficiency in an EBS mouse model, correlating with K17 induction in basal epidermal keratinocytes. Nrf2 induction is brought about..."
Mouse model demonstrates sulforaphane activates Nrf2 to induce compensatory K17 expression in basal keratinocytes, alleviating blistering in K14-deficient EBS.
📊

Related Datasets

1
Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex geo:GSE179508
Human bulk RNA-seq dataset profiling blistered and non-blistered EBS skin, used to define disease-associated signaling programs and prioritize repositionable therapies.
human BULK RNA SEQ n=20
Conditions: blistered EBS skin non-blistered EBS skin
Show evidence (2 references)
GEO:GSE179508 SUPPORT Human Clinical
"In this study, we characterize significant molecular pathways activated in the blisters that form in EBS"
Supports this GEO series as a direct transcriptomic resource for EBS lesional biology.
GEO:GSE179508 SUPPORT Human Clinical
"We implicate the PI3K/AKT/mTOR pathway as central in the EBS disease pathway"
Confirms that the dataset captures disease-relevant signaling programs and supports downstream therapeutic inference.
🔬

Clinical Trials

2
NCT06073132 PHASE_II RECRUITING
Ongoing international phase 2/3 EBShield study evaluating topical diacerein 1% ointment in generalized epidermolysis bullosa simplex.
Target Phenotypes: skin blistering ↗
Show evidence (1 reference)
clinicaltrials:NCT06073132 SUPPORT Human Clinical
"The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS."
This ClinicalTrials.gov record supports an actively recruiting diacerein trial focused specifically on generalized EBS.
NCT03154333 PHASE_II TERMINATED
Terminated randomized phase II study of topical diacerein 1% ointment versus vehicle in epidermolysis bullosa simplex.
Target Phenotypes: skin blistering ↗
Show evidence (1 reference)
clinicaltrials:NCT03154333 SUPPORT Human Clinical
"Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when..."
This ClinicalTrials.gov record supports a disease-specific randomized EBS trial of topical diacerein.
{ }

Source YAML

click to show 
name: Epidermolysis Bullosa Simplex
creation_date: '2026-03-10T00:00:00Z'
updated_date: '2026-05-08T23:53:01Z'
category: Mendelian
description: >-
  Epidermolysis bullosa simplex (EBS) is the most common form of EB,
  characterized by intraepidermal blistering within the basal cell layer.
  Most cases are caused by dominant-negative mutations in KRT5 or KRT14
  encoding keratins 5 and 14 in basal keratinocytes. Blisters generally heal
  without significant scarring. Subtypes range from localized palmoplantar
  blistering to severe generalized forms with herpetiform blistering, and
  include EBS with muscular dystrophy caused by PLEC mutations.
parents:
- Dermatological Disease
- Genetic Disease
disease_term:
  preferred_term: epidermolysis bullosa simplex
  term:
    id: MONDO:0017610
    label: epidermolysis bullosa simplex
mappings:
  icd10cm_mappings:
  - term:
      id: ICD10CM:Q81.0
      label: Epidermolysis bullosa simplex
    mapping_predicate: skos:exactMatch
    mapping_source: ICD-10-CM
    mapping_justification: ICD-10-CM Q81.0 directly names epidermolysis bullosa simplex.
  mondo_mappings:
  - term:
      id: MONDO:0017610
      label: epidermolysis bullosa simplex
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this EBS entry.
classifications:
  harrisons_chapter:
  - classification_value: skin disorder
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin"
      explanation: Supports classifying EBS as a skin disorder because the disease is defined by cutaneous fragility and blistering.
  - classification_value: hereditary disease
    evidence:
    - reference: PMID:22277943
      reference_title: "Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Epidermolysis bullosa simplex (EBS) is a rare genetic condition"
      explanation: Supports classification of EBS as a hereditary disease because it is explicitly described as a genetic condition.
has_subtypes:
- name: EBS Localized (formerly Weber-Cockayne)
  description: >
    Blistering mainly confined to hands and feet, exacerbated by heat and
    increased physical activity. The mildest and most common form of EBS.
    Onset typically in infancy or early childhood.
- name: EBS Intermediate (formerly Koebner)
  description: >
    Generalized non-scarring blistering that may affect any body site.
    More widespread than localized EBS but less severe than the severe form.
    Blisters heal without significant scarring.
- name: EBS Severe (formerly Dowling-Meara)
  description: >
    Grouped herpetiform blistering, palmoplantar keratoderma, and nail
    dystrophy. The most severe keratin-associated form of EBS. Blistering
    tends to improve with age, likely due to the suprabasal switch from
    K5/K14 to K1/K10 during keratinocyte differentiation reducing
    dependence on mutant basal keratins. Improvement with age is common
    in all variants of EBS but is not invariable. The pathognomonic
    transmission electron microscopy (TEM) finding is tonofilament
    (keratin) clumping in basal cells. Laryngeal involvement may occur.
- name: EBS with Muscular Dystrophy
  description: >
    Caused by PLEC mutations leading to skin fragility combined with
    progressive muscular dystrophy. Autosomal recessive inheritance.
    Plectin deficiency disrupts both epidermal and muscle cytoskeletal
    integrity.
- name: EBS Autosomal Recessive (KRT14 null)
  description: >
    Severe, generalized blistering caused by biallelic loss-of-function
    mutations in KRT14 resulting in complete absence of keratin 14 protein.
    More severe than typical dominant EBS.
inheritance:
- name: Autosomal dominant
  description: >
    Most EBS subtypes (localized, intermediate, severe/Dowling-Meara) are
    inherited in an autosomal dominant manner due to dominant-negative
    keratin mutations in KRT5 or KRT14.
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of EBS is established in a proband by: the identification of a heterozygous dominant-negative variant or biallelic loss-of-function variants in KRT5, KRT14, or PLEC"
    explanation: GeneReviews confirms dominant-negative variants in KRT5/KRT14 as a major cause of EBS.
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "18 were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively"
    explanation: Confirms heterozygous (dominant) keratin mutations as a cause of EBS.
- name: Autosomal recessive
  description: >
    EBS with muscular dystrophy (PLEC mutations) and EBS autosomal recessive
    (KRT14 null) are inherited in an autosomal recessive manner.
  evidence:
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common disorder is autosomal recessive disease epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), which is characterized by skin blistering and progressive muscle weakness"
    explanation: Confirms autosomal recessive inheritance of EBS-MD caused by PLEC mutations.
  - reference: PMID:25530118
    reference_title: "Plectin-related skin diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plectin deficiency causes autosomal recessive epidermolysis bullosa simplex (EBS) with involvement of the skin and other organs"
    explanation: Confirms autosomal recessive inheritance pattern for plectin-related EBS.
prevalence:
- population: Global
  notes: >-
    EBS is the most common type of epidermolysis bullosa, accounting for
    approximately 70% of all EB cases. Estimated prevalence is 1 in 30,000
    to 50,000. US National EB Registry data (1986-2002) reported an overall
    EB incidence of 19.57 per million live births, with EBS prevalence
    increasing by 30.4% over the 16-year study period as ascertainment
    improved.
  evidence:
  - reference: PMID:27463098
    reference_title: "Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the overall incidence and prevalence of inherited EB were 19.60 and 8.22 per 1 million live births, respectively"
    explanation: US National EB Registry provides incidence and prevalence estimates for inherited EB including EBS as the most common subtype.
  - reference: PMID:32973163
    reference_title: "Epidermolysis bullosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epidermolysis bullosa (EB) is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible by often minimal trauma"
    explanation: Nature Reviews Disease Primers confirms EB as a group of rare genetic skin fragility disorders with EBS being the most common major type.
pathophysiology:
- name: KRT5/KRT14 Mutations Disrupt Keratin Intermediate Filament Network
  description: >
    Mutations in KRT5 or KRT14 genes disrupt the keratin intermediate filament
    network in basal keratinocytes of the epidermis. Keratins 5 and 14 are
    the obligate type II and type I intermediate filament partners that
    copolymerize to form the 10 nm filament network providing mechanical
    resilience to basal keratinocytes.
  genes:
  - preferred_term: KRT5
    term:
      id: hgnc:6442
      label: KRT5
  - preferred_term: KRT14
    term:
      id: hgnc:6416
      label: KRT14
  biological_processes:
  - preferred_term: intermediate filament organization
    modifier: ABNORMAL
    term:
      id: GO:0045109
      label: intermediate filament organization
  cell_types:
  - preferred_term: epidermal cell
    term:
      id: CL:0000362
      label: epidermal cell
  downstream:
  - target: Dominant-Negative Disruption of Filament Assembly
    description: >
      Mutant keratins poison the filament network by incorporating into
      filaments and destabilizing them.
  evidence:
  - reference: PMID:22277943
    reference_title: "Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most cases of EBS are due to dominantly acting mutations in keratin 14 (K14) or K5, the type I and II intermediate filament (IF) proteins that copolymerize to form a pancytoplasmic network of 10 nm filaments in basal keratinocytes of epidermis and related epithelia"
    explanation: Confirms K5/K14 as the obligate IF pair in basal keratinocytes and dominant mutations as the cause of EBS.
  - reference: PMID:30078200
    reference_title: "Keratins and epidermolysis bullosa simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the most important and most commonly occurring molecular defects in these patients are the defects of keratins 5 and14 (KRT5 and KRT14)"
    explanation: Confirms KRT5 and KRT14 defects as the primary molecular basis of EBS.
- name: Dominant-Negative Disruption of Filament Assembly
  description: >
    Mutant keratins exert a dominant-negative effect by incorporating into
    keratin filaments and poisoning the entire filament network. This
    disrupts filament architecture and leads to keratin aggregate formation,
    particularly under conditions of mechanical or thermal stress.
  biological_processes:
  - preferred_term: intermediate filament cytoskeleton organization
    modifier: ABNORMAL
    term:
      id: GO:0045104
      label: intermediate filament cytoskeleton organization
  cell_types:
  - preferred_term: epidermal cell
    term:
      id: CL:0000362
      label: epidermal cell
  downstream:
  - target: Mechanical Stress-Induced Keratinocyte Cytolysis
    description: >
      Disrupted keratin network renders basal keratinocytes fragile and
      prone to rupture under mechanical stress.
  evidence:
  - reference: PMID:22277943
    reference_title: "Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Defects in K5-K14 filament network architecture cause basal keratinocytes to become fragile, and account for their rupture upon exposure to mechanical trauma"
    explanation: Confirms that disrupted keratin filament architecture causes basal keratinocyte fragility and rupture.
  - reference: PMID:34830328
    reference_title: "Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Keratin aggregates display impaired dynamics of assembly and diminished solubility and appear to be the trigger for endoplasmic reticulum (ER) stress upon being phosphorylated by MAPKs"
    explanation: Confirms that mutant keratins form aggregates with impaired dynamics, triggering downstream ER stress signaling.
- name: Mechanical Stress-Induced Keratinocyte Cytolysis
  description: >
    Basal keratinocytes with disrupted keratin networks rupture (cytolyse)
    when subjected to mechanical trauma. The blistering in EBS is
    intraepidermal, occurring within the basal cell layer rather than at
    tissue interfaces, distinguishing it from junctional and dystrophic EB.
  biological_processes:
  - preferred_term: cell death
    modifier: INCREASED
    term:
      id: GO:0008219
      label: cell death
  cell_types:
  - preferred_term: epidermal cell
    term:
      id: CL:0000362
      label: epidermal cell
  evidence:
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epidermolysis bullosa simplex (EBS) is a mechano-bullous disorder characterized by intraepidermal blistering within the basal keratinocytes as a result of trauma to the skin"
    explanation: Confirms intraepidermal blistering within basal keratinocytes as the hallmark of EBS.
  - reference: PMID:34830328
    reference_title: "Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Epidermolysis bullosa simplex (EBS) is a group of inherited keratinopathies that, in most cases, arise due to mutations in keratins and lead to intraepidermal ruptures"
    explanation: Confirms that keratin mutations lead to intraepidermal rupture.
- name: PLEC Mutations Disrupt Hemidesmosome-Cytoskeleton Linkage
  description: >
    Mutations in PLEC disrupt plectin, a giant cytoskeletal crosslinker that
    connects the keratin intermediate filament network to hemidesmosomes at
    the dermal-epidermal junction and to the desmin cytoskeleton in muscle.
    Loss of plectin causes a dual phenotype affecting both skin (blistering)
    and skeletal muscle (progressive dystrophy).
  genes:
  - preferred_term: PLEC
    term:
      id: hgnc:9069
      label: PLEC
  biological_processes:
  - preferred_term: cell-substrate junction organization
    modifier: ABNORMAL
    term:
      id: GO:0150115
      label: cell-substrate junction organization
  cell_types:
  - preferred_term: epidermal cell
    term:
      id: CL:0000362
      label: epidermal cell
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  downstream:
  - target: Mechanical Stress-Induced Keratinocyte Cytolysis
    description: >
      Disrupted hemidesmosome-cytoskeleton linkage leads to skin fragility.
  evidence:
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plectin is a giant cytoskeletal crosslinker and intermediate filament stabilizing protein. Mutations in the human plectin gene (PLEC) cause several rare diseases that are grouped under the term plectinopathies"
    explanation: Confirms plectin as a cytoskeletal crosslinker whose mutations cause plectinopathies including EBS-MD.
  - reference: PMID:25530118
    reference_title: "Plectin-related skin diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plectin deficiency causes autosomal recessive epidermolysis bullosa simplex (EBS) with involvement of the skin and other organs, such as muscle and gastrointestinal tract, depending on the expression pattern of the defective protein"
    explanation: Confirms plectin deficiency causes EBS with multi-organ involvement including skin and muscle.
- name: Heat Sensitivity of Mutant Keratin Networks
  description: >
    Mutant keratin filament networks are thermally unstable. Elevated
    temperature causes filament breakdown into aggregates, explaining the
    clinical observation that blistering worsens in warm weather and with
    increased perspiration. This is particularly prominent in localized EBS.
  biological_processes:
  - preferred_term: response to heat
    modifier: ABNORMAL
    term:
      id: GO:0009408
      label: response to heat
  evidence:
  - reference: PMID:8586658
    reference_title: "Temperature sensitivity of the keratin cytoskeleton and delayed spreading of keratinocyte lines derived from EBS patients."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "after thermal stress a reduced stability of the keratin filaments was demonstrable in the epidermolysis bullosa simplex cell lines, with filaments breaking into aggregates"
    explanation: Demonstrates that thermal stress causes keratin filament breakdown into aggregates in EBS cell lines, explaining heat-exacerbated blistering.
phenotypes:
- category: Integument
  name: Skin Blistering
  description: >
    Intraepidermal blistering caused by basal keratinocyte fragility.
    Blisters arise at sites of mechanical trauma and generally heal without
    significant scarring, distinguishing EBS from dystrophic EB.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: skin blistering
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma"
    explanation: GeneReviews confirms non-scarring blisters from minor mechanical trauma as the hallmark of EBS.
  - reference: PMID:32973163
    reference_title: "Epidermolysis bullosa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epidermolysis bullosa (EB) is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible by often minimal trauma"
    explanation: Nature Reviews Disease Primers confirms blister formation from minimal trauma as the defining feature of EB.
- category: Integument
  name: Heat-Exacerbated Blistering
  description: >
    Worsening of blistering during warm weather or with increased physical
    activity and perspiration. Caused by thermal instability of mutant
    keratin filament networks. Particularly prominent in localized EBS
    affecting hands and feet.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: heat-exacerbated blistering
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
  evidence:
  - reference: PMID:8586658
    reference_title: "Temperature sensitivity of the keratin cytoskeleton and delayed spreading of keratinocyte lines derived from EBS patients."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "after thermal stress a reduced stability of the keratin filaments was demonstrable in the epidermolysis bullosa simplex cell lines, with filaments breaking into aggregates"
    explanation: Demonstrates thermal instability of mutant keratin filaments, providing the molecular basis for heat-exacerbated blistering.
- category: Integument
  name: Palmoplantar Keratoderma
  description: >
    Thickening of the skin on palms and soles, particularly prominent in
    EBS severe (Dowling-Meara) subtype. May develop progressively with age.
  frequency: FREQUENT
  notes: Primarily seen in EBS severe (Dowling-Meara)
  phenotype_term:
    preferred_term: palmoplantar keratoderma
    term:
      id: HP:0000982
      label: Palmoplantar keratoderma
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation"
    explanation: GeneReviews confirms palmoplantar keratoderma as an additional feature of EBS.
- category: Integument
  name: Herpetiform Blistering Pattern
  description: >
    Grouped (herpetiform) blistering pattern characteristic of EBS severe
    (Dowling-Meara). Blisters cluster in a pattern resembling herpes simplex
    lesions. Associated with keratin filament clumping visible on electron
    microscopy.
  frequency: FREQUENT
  notes: Characteristic of EBS severe (Dowling-Meara) subtype
  phenotype_term:
    preferred_term: grouped herpetiform blistering
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
  evidence:
  - reference: PMID:34830328
    reference_title: "Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mutations in keratins 5/14 or in other genes that encode associated proteins induce structural disarrangements of different strengths depending on their locations in the genes"
    explanation: Confirms that mutation location determines severity of structural disarrangement, explaining the severe herpetiform phenotype in Dowling-Meara EBS.
- category: Integument
  name: Nail Dystrophy
  description: >
    Abnormal nail growth and morphology including thickened, dystrophic, or
    absent nails. Present in severe EBS subtypes and EBS with muscular
    dystrophy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: nail dystrophy
    term:
      id: HP:0008404
      label: Nail dystrophy
  evidence:
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PLEC mutations lead to EBS with nail dystrophy"
    explanation: Confirms nail dystrophy as a recognized feature of PLEC-associated EBS.
- category: Integument
  name: Milia
  description: >
    Small white cysts (milia) that may occur at sites of healed blisters.
    Less prominent in EBS than in dystrophic EB forms.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: milia
    term:
      id: HP:0001056
      label: Milia
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional features can include hyperkeratosis of the palms and soles (keratoderma), nail dystrophy, milia, and hyper- and/or hypopigmentation"
    explanation: GeneReviews lists milia as an additional feature of EBS.
- category: Musculoskeletal
  name: Muscular Dystrophy
  description: >
    Progressive muscular dystrophy in EBS with muscular dystrophy (EBS-MD)
    caused by PLEC mutations. Plectin is essential for muscle cytoskeletal
    integrity. Skeletal muscle biopsies show dystrophic features with
    variation in fiber size, degenerative myofibrillar changes, and
    pathological desmin-positive protein aggregates.
  frequency: OBLIGATE
  notes: Specific to EBS with muscular dystrophy (PLEC mutations)
  phenotype_term:
    preferred_term: progressive muscular dystrophy
    term:
      id: HP:0003560
      label: Muscular dystrophy
  evidence:
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common disorder is autosomal recessive disease epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), which is characterized by skin blistering and progressive muscle weakness"
    explanation: Confirms progressive muscle weakness as a defining feature of EBS-MD.
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Skeletal muscle biopsies from EBS-MD patients and plectin-deficient mice revealed severe dystrophic features with variation in fiber size, degenerative myofibrillar changes, mitochondrial alterations, and pathological desmin-positive protein aggregates"
    explanation: Confirms dystrophic muscle pathology in both human EBS-MD patients and plectin-deficient mouse models.
treatments:
- name: Wound Care
  description: >
    Supportive wound care is the mainstay of EBS management. Includes use
    of non-adherent dressings to protect fragile skin and promote healing
    of blistered areas. Blister lancing with sterile technique to prevent
    blister extension.
  treatment_term:
    preferred_term: wound care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supportive care to protect the skin from blistering; use of dressings that will protect the skin and promote healing of wounds"
    explanation: GeneReviews confirms supportive wound care as the primary management strategy for EBS.
- name: Avoidance of Heat and Friction
  description: >
    Minimizing exposure to heat, excessive physical activity, and friction
    to prevent blistering episodes. Includes wearing loose-fitting clothing,
    soft footwear, and avoiding high ambient temperatures.
  treatment_term:
    preferred_term: avoidance of triggers
    term:
      id: MAXO:0000950
      label: supportive care
  notes: Particularly important for localized EBS where heat is a major trigger.
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Excessive heat exposure may exacerbate blistering and infection. Avoid poorly fitting or coarse-textured clothing/footwear and activities that traumatize the skin"
    explanation: GeneReviews lists heat exposure and skin trauma as agents to avoid in EBS management.
- name: Antiperspirants for Palmoplantar Disease
  description: >
    Topical antiperspirant application to palms and soles to reduce
    perspiration-induced blistering, especially in localized EBS.
  treatment_term:
    preferred_term: topical antiperspirant therapy
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aluminum chloride (20%) applied to palms and soles can reduce sweating and therefore minimize blister formation in some individuals with EBS"
    explanation: GeneReviews confirms aluminum chloride antiperspirant as a treatment to reduce sweating-induced blistering.
- name: Pain Management
  description: >
    Analgesic therapy for pain associated with blistering and erosions.
    May include topical and systemic pain medications depending on severity.
  treatment_term:
    preferred_term: pain management
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Identification and management of specific causes of pain and itching; management with a pain specialist as needed"
    explanation: GeneReviews confirms pain and itch management as part of EBS care.
- name: Physical Therapy
  description: >
    Rehabilitation and physical therapy for patients with EBS-MD to maintain
    mobility and muscle function as muscular dystrophy progresses.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "appropriate footwear and physical therapy to preserve ambulation"
    explanation: GeneReviews confirms physical therapy to preserve ambulation as part of EBS management.
- name: Genetic Counseling
  description: >
    Genetic counseling for affected families regarding inheritance patterns,
    recurrence risk, and prenatal diagnosis options. Important given both
    dominant and recessive forms and significant de novo mutation rate.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings have implications for genetic counseling and prenatal diagnosis for EBS"
    explanation: Confirms the importance of genetic counseling for EBS families, particularly given de novo mutations and mixed inheritance patterns.
- name: Diacerein (Anti-IL-1beta Therapy)
  description: >
    Topical diacerein 1% ointment, an anti-inflammatory agent that inhibits
    IL-1beta signaling. A phase 2/3 crossover trial (n=17) showed 86% of
    diacerein-treated patients achieved >40% blister reduction versus 14%
    with placebo. However, a larger randomized controlled trial (n=54)
    found no significant difference in the primary endpoint (>=60% BSA
    reduction at 8 weeks), though post hoc analysis in severe EBS showed
    a potential signal (46.2% vs 15.4% achieving optimal skin scores).
    Multiple ongoing trials continue to evaluate diacerein in EBS.
  treatment_term:
    preferred_term: diacerein anti-IL-1beta therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:29410318
    reference_title: "Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the patients receiving diacerein, 86% in episode 1 and 37.5% in episode 2 met the primary end point (vs 14% and 17% with placebo, respectively). This effect was still significant after the follow-up"
    explanation: Phase 2/3 crossover trial demonstrating diacerein efficacy in reducing EBS blisters compared to placebo.
  - reference: PMID:37276163
    reference_title: "Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Although there was no significant difference in outcomes between the groups, further study may elucidate the effects of diacerein on EBS lesions, especially in patients with severe EBS"
    explanation: Larger RCT (n=54) did not meet primary endpoint overall, though post hoc analysis suggested benefit in severe EBS subgroup.
- name: Sulforaphane (Nrf2 Activator, Preclinical)
  description: >
    Sulforaphane, a natural product from cruciferous vegetables, activates
    the Nrf2 transcription factor to induce compensatory keratins K16/K17
    in basal keratinocytes. In an EBS mouse model with K14 deficiency,
    sulforaphane treatment alleviated blistering by upregulating K17
    expression. This represents an attractive preclinical approach
    exploiting functional redundancy within the keratin gene family.
  notes: Preclinical stage only; not yet tested in human clinical trials for EBS.
  treatment_term:
    preferred_term: sulforaphane Nrf2 activator therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:17724334
    reference_title: "Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "treatment with a pharmacological activator of Nrf2, two transcription factors eliciting distinct transcriptional programs, alleviates the blistering caused by a K14 deficiency in an EBS mouse model, correlating with K17 induction in basal epidermal keratinocytes. Nrf2 induction is brought about by treatment with sulforaphane, a natural product"
    explanation: Mouse model demonstrates sulforaphane activates Nrf2 to induce compensatory K17 expression in basal keratinocytes, alleviating blistering in K14-deficient EBS.
clinical_trials:
- name: NCT06073132
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Ongoing international phase 2/3 EBShield study evaluating topical
    diacerein 1% ointment in generalized epidermolysis bullosa simplex.
  target_phenotypes:
  - preferred_term: skin blistering
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
  evidence:
  - reference: clinicaltrials:NCT06073132
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS."
    explanation: This ClinicalTrials.gov record supports an actively recruiting diacerein trial focused specifically on generalized EBS.
  notes: >-
    ClinicalTrials.gov currently lists combined phase 2 and phase 3
    designations; the schema entry uses PHASE_II because only one phase value
    can be represented.
- name: NCT03154333
  phase: PHASE_II
  status: TERMINATED
  description: >-
    Terminated randomized phase II study of topical diacerein 1% ointment
    versus vehicle in epidermolysis bullosa simplex.
  target_phenotypes:
  - preferred_term: skin blistering
    term:
      id: HP:0008066
      label: Abnormal blistering of the skin
  evidence:
  - reference: clinicaltrials:NCT03154333
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS."
    explanation: This ClinicalTrials.gov record supports a disease-specific randomized EBS trial of topical diacerein.
  notes: >-
    ClinicalTrials.gov currently lists this study as terminated for futility.
genetic:
- name: KRT5
  association: Causative
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autosomal dominant EBS is associated with either a heterozygous dominant-negative variant in KRT5, KRT14, or PLEC"
      explanation: GeneReviews confirms autosomal dominant inheritance for KRT5 via dominant-negative variants.
  notes: >
    Keratin 5 gene on chromosome 12q13.13. Encodes the type II keratin that
    pairs with keratin 14 in basal keratinocytes. Dominant-negative
    missense mutations, particularly in the helix boundary motifs, cause
    EBS. Hotspot mutations in the 1A and 2B rod domain helix boundaries
    correlate with more severe phenotypes.
  evidence:
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "18 were found to harbor heterozygous mutations in the keratin 5 or keratin 14 genes, KRT5 and KRT14, respectively"
    explanation: Confirms heterozygous KRT5 mutations as a cause of EBS.
  - reference: PMID:30078200
    reference_title: "Keratins and epidermolysis bullosa simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the most important and most commonly occurring molecular defects in these patients are the defects of keratins 5 and14 (KRT5 and KRT14)"
    explanation: Confirms KRT5 as one of the two principal genes mutated in EBS.
- name: KRT14
  association: Causative
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autosomal dominant EBS is associated with either a heterozygous dominant-negative variant in KRT5, KRT14, or PLEC"
      explanation: GeneReviews confirms autosomal dominant inheritance for KRT14.
  - name: Autosomal recessive
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autosomal recessive EBS is associated with either biallelic loss-of-function variants in KRT5, KRT14, or PLEC"
      explanation: GeneReviews confirms autosomal recessive inheritance for biallelic KRT14 loss-of-function variants.
  notes: >
    Keratin 14 gene on chromosome 17q21.2. Encodes the type I keratin
    partner of keratin 5 in basal keratinocytes. Dominant-negative missense
    mutations cause EBS localized through severe. Biallelic loss-of-function
    (null) mutations cause autosomal recessive EBS with severe generalized
    blistering.
  evidence:
  - reference: PMID:22277943
    reference_title: "Defining keratin protein function in skin epithelia: epidermolysis bullosa simplex and its aftermath."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most cases of EBS are due to dominantly acting mutations in keratin 14 (K14) or K5"
    explanation: Confirms dominant KRT14 mutations as a major cause of EBS.
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "many cases result from de novo mutations in KRT5 and KRT14 genes"
    explanation: Confirms that many EBS cases arise from de novo KRT14 mutations.
- name: PLEC
  association: Causative
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autosomal recessive EBS is associated with either biallelic loss-of-function variants in KRT5, KRT14, or PLEC"
      explanation: GeneReviews confirms autosomal recessive inheritance for PLEC.
  notes: >
    Plectin gene on chromosome 8q24.3. Encodes a giant (>500 kDa)
    cytoskeletal crosslinker protein. Biallelic loss-of-function mutations
    cause EBS with muscular dystrophy. Plectin links the keratin
    intermediate filament network to hemidesmosomes in skin and to the
    desmin cytoskeleton in muscle.
  evidence:
  - reference: PMID:34572129
    reference_title: "Muscle-Related Plectinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in the human plectin gene (PLEC) cause several rare diseases that are grouped under the term plectinopathies"
    explanation: Confirms PLEC mutations as causative for plectinopathies including EBS-MD.
  - reference: PMID:16098032
    reference_title: "Epidermolysis bullosa simplex: recurrent and de novo mutations in the KRT5 and KRT14 genes, phenotype/genotype correlations, and implications for genetic counseling and prenatal diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in 14 cases, the disease was associated with mutations in both alleles of the plectin gene"
    explanation: Confirms biallelic plectin mutations in EBS patients, establishing recessive inheritance.
- name: DST
  association: Causative
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "biallelic pathogenic variants in CD151, DST, or EXPH5"
      explanation: GeneReviews confirms autosomal recessive inheritance for DST.
  notes: >
    Dystonin gene (also known as BPAG1) on chromosome 6p12.1. Encodes a
    cytoskeletal linker protein related to plectin. Rare biallelic mutations
    cause EBS with additional features.
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in CD151, DST, or EXPH5"
    explanation: GeneReviews lists DST as a gene with biallelic pathogenic variants causing autosomal recessive EBS.
- name: EXPH5
  association: Causative
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "biallelic pathogenic variants in CD151, DST, or EXPH5"
      explanation: GeneReviews confirms autosomal recessive inheritance for EXPH5.
  notes: >
    Exophilin 5 gene on chromosome 11q22.3. Encodes a Rab27b effector
    involved in melanosome and lamellar body transport. Biallelic mutations
    cause a rare autosomal recessive form of EBS.
  evidence:
  - reference: PMID:20301543
    reference_title: "Epidermolysis Bullosa Simplex."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "biallelic pathogenic variants in CD151, DST, or EXPH5"
    explanation: GeneReviews lists EXPH5 as a gene with biallelic pathogenic variants causing autosomal recessive EBS.
- name: KLHL24
  association: Causative
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:20301543
      reference_title: "Epidermolysis Bullosa Simplex."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a heterozygous pathogenic variant in KLHL24"
      explanation: GeneReviews confirms autosomal dominant inheritance for KLHL24.
  gene_term:
    preferred_term: KLHL24
    term:
      id: hgnc:25947
      label: KLHL24
  notes: >
    Kelch-like family member 24 gene on chromosome 3q27.1. Encodes a
    CUL3-RBX1 ubiquitin ligase substrate receptor. Gain-of-function
    mutations in the translation initiation codon (c.1A>G, c.2T>C) produce
    a truncated protein (KLHL24-deltaN28) that escapes autoubiquitination
    and causes excessive ubiquitin-mediated degradation of keratin 14
    (KRT14). Patients present with extensive skin denudation at birth and
    dilated cardiomyopathy. The c.1A>G mutation has occurred de novo and is
    recurrent across unrelated families from different countries.
  evidence:
  - reference: PMID:27798626
    reference_title: "Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified start-codon mutations in the KLHL24 gene in five patients with EB."
    explanation: Identifies KLHL24 start-codon mutations as a novel cause of EBS through stabilized truncated protein that excessively degrades KRT14.
  - reference: PMID:27889062
    reference_title: "Monoallelic Mutations in the Translation Initiation Codon of KLHL24 Cause Skin Fragility."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "monoallelic mutations, c.1A>G and c.2T>C, in the translation initiation codon of the gene encoding kelch-like protein 24 (KLHL24) in 14 individuals with a distinct skin-fragility phenotype and skin cleavage within basal keratinocytes"
    explanation: Independently confirms KLHL24 initiation codon mutations in 14 individuals with skin fragility and basal keratinocyte cleavage.
datasets:
- accession: geo:GSE179508
  title: Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex
  description: >-
    Human bulk RNA-seq dataset profiling blistered and non-blistered EBS skin,
    used to define disease-associated signaling programs and prioritize
    repositionable therapies.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 20
  conditions:
  - blistered EBS skin
  - non-blistered EBS skin
  evidence:
  - reference: GEO:GSE179508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we characterize significant molecular pathways activated in the blisters that form in EBS"
    explanation: Supports this GEO series as a direct transcriptomic resource for EBS lesional biology.
  - reference: GEO:GSE179508
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We implicate the PI3K/AKT/mTOR pathway as central in the EBS disease pathway"
    explanation: Confirms that the dataset captures disease-relevant signaling programs and supports downstream therapeutic inference.
references:
- reference: PMID:20301543
  title: "Epidermolysis Bullosa Simplex."
  tags:
  - GeneReviews
  findings: []
- reference: DOI:10.1101/cshperspect.a041229
  title: Stairways to Advanced Therapies for Epidermolysis Bullosa
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Stairways to Advanced Therapies for Epidermolysis Bullosa
    supporting_text: Stairways to Advanced Therapies for Epidermolysis Bullosa
- reference: DOI:10.1111/bjd.18128
  title: Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
    supporting_text: Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
- reference: DOI:10.1111/bjd.18921
  title: Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
    supporting_text: Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
- reference: DOI:10.1111/jdv.18637
  title: Epidemiology of inherited epidermolysis bullosa in Germany
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidemiology of inherited epidermolysis bullosa in Germany
    supporting_text: 'Epidermolysis bullosa (EB) is a rare genetic disorder manifesting with skin and mucosal membrane blistering in different degrees of severity.ObjectiveEpidemiological data from different countries have been published, but none are available from Germany.MethodsIn this population‐based cross‐sectional study, people living with EB in Germany were identified using the following sources: academic hospitals, diagnostic laboratories and patient organization.ResultsOur study indicates an overall EB incidence of 45 per million live births in Germany.'
    evidence:
    - reference: DOI:10.1111/jdv.18637
      reference_title: Epidemiology of inherited epidermolysis bullosa in Germany
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'Epidermolysis bullosa (EB) is a rare genetic disorder manifesting with skin and mucosal membrane blistering in different degrees of severity.ObjectiveEpidemiological data from different countries have been published, but none are available from Germany.MethodsIn this population‐based cross‐sectional study, people living with EB in Germany were identified using the following sources: academic hospitals, diagnostic laboratories and patient organization.ResultsOur study indicates an overall EB incidence of 45 per million live births in Germany.'
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1111/jdv.18692
  title: Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China
    supporting_text: Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic blistering disorders.ObjectivesThe objective was to analyse the genotype–phenotype correlation in EB among Chinese individuals.MethodsNext‐generation sequencing and Sanger sequencing were performed to genetically confirm clinically diagnosed EB.
    evidence:
    - reference: DOI:10.1111/jdv.18692
      reference_title: Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic blistering disorders.ObjectivesThe objective was to analyse the genotype–phenotype correlation in EB among Chinese individuals.MethodsNext‐generation sequencing and Sanger sequencing were performed to genetically confirm clinically diagnosed EB.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1111/pde.15440
  title: Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane.
    supporting_text: Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane.
    evidence:
    - reference: DOI:10.1111/pde.15440
      reference_title: Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1177/0300985819900354
  title: 'Spontaneous <i>KRT5</i> Gene Mutation in Rhesus Macaques ( <i>Macaca mulatta</i> ): A Novel Nonhuman Primate Model of Epidermolysis Bullosa Simplex'
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility.
    supporting_text: Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility.
    evidence:
    - reference: DOI:10.1177/0300985819900354
      reference_title: 'Spontaneous <i>KRT5</i> Gene Mutation in Rhesus Macaques ( <i>Macaca mulatta</i> ): A Novel Nonhuman Primate Model of Epidermolysis Bullosa Simplex'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1186/s13023-022-02433-3
  title: A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses.
    supporting_text: Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses.
    evidence:
    - reference: DOI:10.1186/s13023-022-02433-3
      reference_title: A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1542/neo.22-7-e438
  title: Diagnosis and Care of the Newborn with Epidermolysis Bullosa
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin.
    supporting_text: Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin.
    evidence:
    - reference: DOI:10.1542/neo.22-7-e438
      reference_title: Diagnosis and Care of the Newborn with Epidermolysis Bullosa
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.3390/ijms25179495
  title: 'Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives'
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma.
    supporting_text: Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma.
    evidence:
    - reference: DOI:10.3390/ijms25179495
      reference_title: 'Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma.
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
- reference: DOI:10.1038/s41572-020-0210-0
  title: Epidermolysis bullosa
  found_in:
  - Epidermolysis_Bullosa_Simplex-deep-research-falcon.md
  findings:
  - statement: Epidermolysis bullosa
    supporting_text: Epidermolysis bullosa
    evidence:
    - reference: DOI:10.1038/s41572-020-0210-0
      reference_title: Epidermolysis bullosa
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Epidermolysis bullosa
      explanation: Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
📚

References & Deep Research

References

12
PMID:20301543
Epidermolysis Bullosa Simplex.
No top-level findings curated for this source.
DOI:10.1101/cshperspect.a041229
Stairways to Advanced Therapies for Epidermolysis Bullosa
1 finding
Stairways to Advanced Therapies for Epidermolysis Bullosa
"Stairways to Advanced Therapies for Epidermolysis Bullosa"
DOI:10.1111/bjd.18128
Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
1 finding
Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa
"Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa"
DOI:10.1111/bjd.18921
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
1 finding
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility"
DOI:10.1111/jdv.18637
Epidemiology of inherited epidermolysis bullosa in Germany
1 finding
Epidemiology of inherited epidermolysis bullosa in Germany
"Epidermolysis bullosa (EB) is a rare genetic disorder manifesting with skin and mucosal membrane blistering in different degrees of severity.ObjectiveEpidemiological data from different countries have been published, but none are available from Germany.MethodsIn this population‐based..."
Show evidence (1 reference)
DOI:10.1111/jdv.18637 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) is a rare genetic disorder manifesting with skin and mucosal membrane blistering in different degrees of severity.ObjectiveEpidemiological data from different countries have been published, but none are available from Germany.MethodsIn this population‐based..."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1111/jdv.18692
Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China
1 finding
Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from China
"Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic blistering disorders.ObjectivesThe objective was to analyse the genotype–phenotype correlation in EB among Chinese individuals.MethodsNext‐generation sequencing and Sanger sequencing were performed to genetically..."
Show evidence (1 reference)
DOI:10.1111/jdv.18692 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic blistering disorders.ObjectivesThe objective was to analyse the genotype–phenotype correlation in EB among Chinese individuals.MethodsNext‐generation sequencing and Sanger sequencing were performed to genetically..."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1111/pde.15440
Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa
1 finding
Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane.
"Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane."
Show evidence (1 reference)
DOI:10.1111/pde.15440 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) features skin and mucosal fragility due to pathogenic variants in genes encoding components of the cutaneous basement membrane."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1177/0300985819900354
Spontaneous <i>KRT5</i> Gene Mutation in Rhesus Macaques ( <i>Macaca mulatta</i> ): A Novel Nonhuman Primate Model of Epidermolysis Bullosa Simplex
1 finding
Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility.
"Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility."
Show evidence (1 reference)
DOI:10.1177/0300985819900354 SUPPORT Model Organism
"Epidermolysis bullosa simplex (EBS) is an inherited skin disorder characterized by increased skin and mucous membrane fragility."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1186/s13023-022-02433-3
A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex
1 finding
Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses.
"Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses."
Show evidence (1 reference)
DOI:10.1186/s13023-022-02433-3 SUPPORT Human Clinical
"Epidermolysis bullosa simplex (EBS) comprises a group of rare, blistering genodermatoses."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1542/neo.22-7-e438
Diagnosis and Care of the Newborn with Epidermolysis Bullosa
1 finding
Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin.
"Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin."
Show evidence (1 reference)
DOI:10.1542/neo.22-7-e438 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) is a group of rare genetic disorders that are characterized by fragile skin."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.3390/ijms25179495
Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives
1 finding
Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma.
"Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma."
Show evidence (1 reference)
DOI:10.3390/ijms25179495 SUPPORT Human Clinical
"Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of mechanobullous diseases characterized by non-scarring blisters and erosions on the skin and mucous membranes upon mechanical trauma."
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.
DOI:10.1038/s41572-020-0210-0
Epidermolysis bullosa
1 finding
Epidermolysis bullosa
"Epidermolysis bullosa"
Show evidence (1 reference)
DOI:10.1038/s41572-020-0210-0 SUPPORT Other
"Epidermolysis bullosa"
Deep research cited this publication as relevant literature for Epidermolysis Bullosa Simplex.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 50 citations 2026-05-08T16:34:19.918654

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Epidermolysis Bullosa Simplex
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Epidermolysis Bullosa Simplex covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Epidermolysis Bullosa Simplex (EBS)

Executive summary

Epidermolysis bullosa simplex (EBS) is a Mendelian skin-fragility disorder within the inherited epidermolysis bullosa (EB) spectrum, defined by intraepidermal blistering due to cleavage within the basal layer of keratinocytes, typically triggered by minor mechanical trauma. (Has et al., Br J Dermatol, 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 2-3). The current (international consensus) classification organizes EB into four major types—EBS, junctional EB, dystrophic EB, and Kindler EB—based primarily on level of cleavage and molecular etiology. (Has et al., 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 1-2).

Key 2023–2024 advances emphasized in recent reviews include (i) a more explicit framing of EBS as both a mechanical fragility disorder and a disease with inflammatory/stress-response signaling cascades downstream of keratin disruption, and (ii) continued growth of symptom-targeted therapies through drug repurposing and targeted topical approaches. (Bchetnia et al., Int J Mol Sci, 2024-08, https://doi.org/10.3390/ijms25179495) (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

1. Disease information

1.1 What is the disease?

EBS is an inherited mechanobullous (mechanically induced blistering) genodermatosis characterized by skin fragility with blistering/erosions after minor trauma, with tissue cleavage occurring within the basal keratinocyte layer of the epidermis (intraepidermal). (Has et al., 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 2-3). A 2024 EBS-focused review similarly defines EBS as “recurrent blister formation within the basal layer of the epidermis,” most often due to dominant keratin 5/14 mutations. (Bchetnia et al., 2024-08, https://doi.org/10.3390/ijms25179495) (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

1.2 Key identifiers (OMIM, Orphanet, ICD-10/ICD-11, MeSH, MONDO)

Not available from the retrieved evidence snippets. The sources available in this run did not provide explicit OMIM, Orphanet, ICD-10/ICD-11, MeSH, or MONDO identifiers for EBS. (has2020consensusreclassificationof pages 2-3, bchetnia2024pathologicalmechanismsinvolved pages 1-2, has2019clinicalpracticeguidelines pages 1-2).

1.3 Common synonyms / alternative names

Common clinical subtype names used in the contemporary literature include: - Localized EBS (historical eponym: Weber–Cockayne) - Intermediate generalized EBS (historical eponym: Köebner) - Severe generalized EBS (historical eponym: Dowling–Meara) (Has et al., 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 2-3).

1.4 Evidence source type

The evidence synthesized here is primarily from aggregated disease-level resources and cohorts/registries (consensus classification, clinical practice guidelines, epidemiology capture–recapture study, multi-country patient-reported outcomes survey), complemented by clinical-trial registry records and mechanistic review literature. (has2020consensusreclassificationof pages 1-2, has2019clinicalpracticeguidelines pages 1-2, has2023epidemiologyofinherited pages 7-7, so2022aglobalcrosssectional pages 1-2, NCT02470689 chunk 1).

2. Etiology

2.1 Disease causal factors

Genetic (primary): EBS most often results from autosomal dominant pathogenic variants in KRT5 or KRT14 encoding keratin 5 and keratin 14 intermediate filament proteins in basal keratinocytes. (Bchetnia et al., 2024-08, https://doi.org/10.3390/ijms25179495) (bchetnia2024pathologicalmechanismsinvolved pages 1-2). The 2020 international consensus explicitly frames EBS as blistering from cleavage within basal keratinocytes and notes multiple EBS-associated genes beyond keratins, including newer additions such as KLHL24. (Has et al., 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 2-3).

Additional (rarer) EBS genes (examples): PLEC, KLHL24, DST, EXPH5, CD151. (Bchetnia et al., 2024-08, https://doi.org/10.3390/ijms25179495) (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

2.2 Risk factors

  • Genetic risk factor: carrying a pathogenic variant in a causal EBS gene (e.g., KRT5/KRT14). (bchetnia2024pathologicalmechanismsinvolved pages 1-2)
  • De novo and mosaic mutations: In a large China cohort, de novo mutations were reported as common in EBS (63.8%), and mosaicism was observed (~5.4% in dominant EBS), highlighting that absence of family history does not exclude EBS. (Chen et al., JEADV, 2023-11, https://doi.org/10.1111/jdv.18692) (chen2023genotypeandphenotype pages 1-1).

Environmental/triggering factors (non-causal but exacerbating): mechanical friction/trauma is the key trigger for blister formation in EB generally and EBS specifically. (Has et al., 2020-03, https://doi.org/10.1111/bjd.18921) (has2020consensusreclassificationof pages 1-2).

2.3 Protective factors

No validated protective genetic or environmental factors were identified in the retrieved evidence excerpts.

2.4 Gene–environment interactions

The retrieved evidence supports a strong mechanical trigger (friction) interacting with genetically determined structural fragility, but does not provide quantitative gene–environment interaction effect sizes.

3. Phenotypes

3.1 Phenotype spectrum and subtype distribution

EBS is commonly divided into localized, intermediate generalized, and severe generalized forms. (Has et al., 2020-03) (has2020consensusreclassificationof pages 2-3).

Population-based and cohort data show subtype distributions vary by region and ascertainment: - Germany (capture–recapture, inherited EB): EBS subtypes most commonly localized (39.5%) and severe (14.7%), with 33.4% of EBS not further subclassified. (Has et al., JEADV, 2023-11, https://doi.org/10.1111/jdv.18637) (has2023epidemiologyofinherited pages 5-6). - China (441 EB patients): EBS comprised ~23.4% of the EB cohort; among EBS cases, localized 17.5%, intermediate 35.0%, severe 27.2%. (Chen et al., 2023-11, https://doi.org/10.1111/jdv.18692) (chen2023genotypeandphenotype pages 2-2).

3.2 Common clinical manifestations (patient-reported)

In the largest international cross-sectional EBS patient-reported outcomes survey (n=214; mean age 32.8 years), respondents reported: blisters 93%, recurrent wounds 89%, pain 74%, chronic wounds 59%, itch 55%, and difficulty walking 44%; the mean QOLEB score was 14.7 (SD 7.5) indicating a moderate impact on quality of life, and 12% reported regular opiate use. (So et al., Orphanet J Rare Dis, 2022-07, https://doi.org/10.1186/s13023-022-02433-3) (so2022aglobalcrosssectional pages 1-2).

More granular QOLEB impacts among those completing all items (70/214): 41% reported frequent/constant pain, 93% unable to participate in sports, 79% difficulty moving outside the home, and high emotional burden (frustration 99%, anxiety 70%, depression 54%). (So et al., 2022-07) (so2022aglobalcrosssectional pages 6-8).

3.3 Quality of life impact

QOL impact is measurable and moderate on average in the survey above (QOLEB mean 14.7), with substantial mobility limitations and psychosocial effects. (so2022aglobalcrosssectional pages 6-8).

3.4 Suggested HPO terms (examples; not exhaustive)

Based on the phenotype descriptions in the cited studies, suitable HPO terms include: - Skin blistering: HP:0008064 (Blistering of the skin) - Skin fragility: HP:0001034 (Fragile skin) - Erosions/ulcerations: HP:0001058 (Skin erosion) / HP:0000974 (Skin ulcer) - Pain: HP:0012531 (Pain) - Pruritus: HP:0000989 (Pruritus) - Difficulty walking / impaired mobility: HP:0002355 (Difficulty walking) - Palmoplantar keratoderma (for localized plantar disease): HP:0000972 (Palmoplantar keratoderma)

4. Genetic / molecular information

4.1 Causal genes (major)

  • KRT5 and KRT14 are the predominant genes for dominant EBS. (bchetnia2024pathologicalmechanismsinvolved pages 1-2)

Cohort support: - In a Middle Eastern EB cohort (n=151), EBS was 64% (97/151); within EBS cases, KRT5 accounted for 46% (45/97) and KRT14 for 43% (42/97). (Bergson et al., Pediatr Dermatol, 2023-10, https://doi.org/10.1111/pde.15440) (bergson2023clinicalandmolecular pages 1-2).

4.2 Other reported EBS genes

Rarer EBS-associated genes cited in the recent EBS review and consensus classification include PLEC, KLHL24, DST, EXPH5, CD151. (bchetnia2024pathologicalmechanismsinvolved pages 1-2, has2020consensusreclassificationof pages 2-3).

In the China cohort, PLEC and KLHL24 variants were each found in four cases (cohort-wide). (chen2023genotypeandphenotype pages 3-3).

4.3 Pathogenic variant types and genotype–phenotype considerations

  • The China cohort highlights recurrent keratin hotspots and domain clustering, including classic KRT14 p.Arg125 substitutions (e.g., p.R125H/C/S/L) and variants in keratin α-helical domains (1A/1B/2A/2B) and linkers. (chen2023genotypeandphenotype pages 4-4).
  • The Middle Eastern cohort reported a phenotype association: truncal involvement was more common in KRT14-associated EBS than KRT5-associated EBS (p<0.05). (bergson2023clinicalandmolecular pages 1-2).

Somatic vs germline: Mosaicism in dominant EBS was reported (~5.4% in one large cohort), supporting consideration of mosaicism in genetic testing/interpretation. (chen2023genotypeandphenotype pages 1-1).

4.4 Suggested ontology/annotation terms

  • GO biological processes (examples): keratinocyte differentiation; response to mechanical stimulus; inflammatory response; cellular response to endoplasmic reticulum stress.
  • Cell types (Cell Ontology, examples): basal keratinocyte (epidermal basal cell); epidermal keratinocyte.

5. Environmental information

EBS is not infectious; its primary cause is genetic. Mechanical trauma/friction is the canonical trigger for blistering in EB. (has2020consensusreclassificationof pages 1-2). No specific toxins, lifestyle exposures, or pathogens were identified in the retrieved evidence as causal contributors.

6. Mechanism / pathophysiology (current understanding, 2023–2024 emphasis)

6.1 Core causal chain (structural fragility)

1) Primary trigger: pathogenic variants (often dominant) in KRT5 or KRT14. 2) Cellular consequence: disruption of the basal keratin intermediate filament network, with keratin aggregation and cytoskeletal instability. 3) Tissue consequence: basal keratinocyte fragility leading to intraepidermal cleavage and blistering with minor trauma. (Bchetnia et al., 2024-08) (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

6.2 Inflammatory/stress signaling cascades (important recent framing)

A key 2024 EBS review emphasizes that disruptive KRT5/KRT14 mutations “will not only structurally impair the cytoskeleton, but it will also activate a cascade of biochemical mechanisms,” including ER stress and release of pro-inflammatory molecules. (Bchetnia et al., 2024-08) (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

Clinical-trial rationale (Dowling–Meara/generalized severe subtype) highlights an IL-1β/JNK axis: upregulation of interleukin-1β (IL-1β) and activation of the JNK stress pathway, with in vitro data that blocking IL‑1β or applying diacerein reduced IL‑1β and K14 expression and improved keratinocyte stress resistance. (ClinicalTrials.gov record NCT02470689; 2015; https://clinicaltrials.gov/study/NCT02470689) (NCT02470689 chunk 1).

6.3 Transcriptomics / molecular profiling

The 2024 mechanistic review states that multiple gene expression studies in mouse models and human keratinocytes identify EBS gene expression signatures involving immunological mediators, keratins, and junction components, with particular emphasis on inflammation as a functional biological process. (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

7. Anatomical structures affected

7.1 Organ/tissue level

  • Primary affected tissue: skin (epidermis) with basal-layer keratinocyte cleavage. (has2020consensusreclassificationof pages 2-3)
  • Mucosal involvement can occur (particularly in more severe generalized forms) within the broader EB spectrum. (Rosa et al., Cold Spring Harb Perspect Biol, 2023-09, https://doi.org/10.1101/cshperspect.a041229) (rosa2023stairwaystoadvanced pages 1-3).

7.2 Suggested UBERON terms (examples)

  • Skin: UBERON:0002097
  • Epidermis: UBERON:0001003

7.3 Suggested GO cellular component terms (examples)

  • Intermediate filament cytoskeleton; keratin filament.

8. Temporal development (onset and progression)

Severe EBS forms can present at or near birth and may be associated with severe complications; milder localized forms may be recognized later and can be underdiagnosed. (Has et al., 2020-03) (has2020consensusreclassificationof pages 2-3). In Germany, EBS incidence was noted as potentially underestimated due to later diagnosis/missed diagnosis. (Has et al., 2023-11) (has2023epidemiologyofinherited pages 7-7).

9. Inheritance and population

9.1 Inheritance pattern

EBS is most often autosomal dominant, with autosomal recessive forms also described. (has2020consensusreclassificationof pages 2-3).

9.2 Epidemiology (recent quantitative estimates)

Germany (population-based capture–recapture; incidence years 2003–2019; age assessed as of 2022-04-01): - Overall inherited EB incidence: 45.09 per 1,000,000 live births (≈ 1 in 22,178 live births per year) - EBS incidence: 14.93 per 1,000,000 live births (≈ 1 in 66,979) - Estimated prevalence (all EB): 54.02 per million; EBS prevalence: 28.44 per million (Has et al., JEADV, 2023-11, https://doi.org/10.1111/jdv.18637) (has2023epidemiologyofinherited pages 5-6, has2023epidemiologyofinherited pages 7-7).

United States (review-level estimates as reported in a therapeutics-focused review): incidence and prevalence were stated as 11.1 per million and 19.6 per million, respectively. (Rosa et al., 2023-09) (rosa2023stairwaystoadvanced pages 1-3).

10. Diagnostics

10.1 Diagnostic approach (guidelines and current practice)

The 2019 clinical practice guidelines for laboratory diagnosis of EB recommend that laboratory diagnosis be initiated “as soon as there is clinical suspicion,” and state: “Genetic testing is always recommended” (index case and, if possible, parents). (Has et al., Br J Dermatol, 2019-08, https://doi.org/10.1111/bjd.18128) (has2019clinicalpracticeguidelines pages 1-2).

Immunofluorescence mapping (IFM): Recommended as an early test to obtain rapid diagnosis/prognosis and to prioritize and interpret genetic testing. In neonates, the guideline notes IFM can provide diagnosis “within hours.” (Has et al., 2019-08) (has2019clinicalpracticeguidelines pages 6-7).

Parallel testing in neonates: Neonatal review recommendations: “obtain a skin biopsy for IFM and a blood sample for genetic testing to be run in parallel.” (Lucky et al., NeoReviews, 2021-07, https://doi.org/10.1542/neo.22-7-e438) (lucky2021diagnosisandcare pages 3-5).

Specimen handling (selected technical details): 3–4 mm punch biopsy for IFM in Michel media; 2–3 mm punch biopsy for EM in glutaraldehyde fixative. (Lucky et al., 2021-07) (lucky2021diagnosisandcare pages 3-5).

Genetic testing modalities: Guidelines describe use of targeted EB gene panels/NGS, WES, and Sanger sequencing, with escalation to RNA-based or copy-number approaches when needed. (Has et al., 2019-08) (has2019clinicalpracticeguidelines pages 10-11). The neonatal review notes NGS targeted panels typically have ~1 month turnaround and are more cost-effective than sequential Sanger sequencing. (Lucky et al., 2021-07) (lucky2021diagnosisandcare pages 3-5).

10.2 Differential diagnosis

Not systematically extracted from the available evidence excerpts in this run.

11. Outcomes / prognosis

EBS prognosis is heterogeneous: localized forms often have near-normal life expectancy, whereas severe generalized forms can be associated with serious complications and early mortality in some cases. (Has et al., 2020-03) (has2020consensusreclassificationof pages 2-3). A Germany EB epidemiology study reported mortality metrics primarily for JEB/DEB; it did not provide an EBS-specific mean age at death in the extracted snippets. (has2023epidemiologyofinherited pages 7-8).

12. Treatment

12.1 Standard-of-care (real-world implementation)

There is no universally curative treatment for EB; management is multidisciplinary and supportive (wound care, symptom control, complication prevention). (Bardhan et al., Nat Rev Dis Primers, 2020-09, https://doi.org/10.1038/s41572-020-0210-0) (bardhan2020epidermolysisbullosa pages 1-2).

12.2 Drug repurposing and targeted therapies in EBS (selected examples)

(A) Topical diacerein (anti–IL-1β axis)

A Phase 2 randomized crossover trial record for EBS–Dowling–Meara (generalized severe) describes topical 1% diacerein cream targeting IL‑1β/JNK-associated disease biology. The record reports a prior pilot (n=5) with blister reductions −78% and −66% from baseline within two weeks in an armpit model. (ClinicalTrials.gov NCT02470689; 2015; https://clinicaltrials.gov/study/NCT02470689) (NCT02470689 chunk 1).

MAXO suggestions (examples): topical pharmacotherapy; anti-inflammatory therapy.

(B) mTOR inhibition (topical sirolimus)

A 2024 EBS mechanism/therapeutics review describes topical sirolimus as an mTOR inhibitor with reported clinical improvement in two patients with plantar keratoderma, and summarizes topical sirolimus as a repositioning approach supported by transcriptomic rationale. (Bchetnia et al., 2024-08) (bchetnia2024pathologicalmechanismsinvolved pages 10-12, bchetnia2024pathologicalmechanismsinvolved pages 13-14).

MAXO suggestions: topical rapamycin therapy; mTOR inhibitor therapy.

(C) Botulinum toxin for plantar disease (symptom and blister reduction)

The same 2024 review summarizes small studies/case reports of botulinum toxin (types A and B) injected into feet of patients with localized and severe EBS, with reported improvements in blistering and pedal pain (and odor in a pediatric case). (Bchetnia et al., 2024-08) (bchetnia2024pathologicalmechanismsinvolved pages 10-12, bchetnia2024pathologicalmechanismsinvolved pages 13-14).

MAXO suggestions: botulinum toxin injection; pain management.

12.3 Clinical trials (selected EBS-relevant trials and endpoints)

A major EB review lists interventional trials relevant to EBS including: - Diacerein Phase II placebo-controlled trial NCT03154333 with endpoint described as proportion achieving ≥60% improvement in affected assessed body surface area. - Sirolimus Phase II placebo-controlled trial NCT03016715 with endpoints including foot health status, pedometer progress, plantar defect size, disease severity, and quality of life. - Botulinum toxin randomized crossover trial for localized EBS NCT03453632 with endpoints including plantar pain/tolerability. (Bardhan et al., 2020-09) (bardhan2020epidermolysisbullosa pages 20-21).

Note: For trial phase/status/enrollment details beyond those in the cited excerpt, ClinicalTrials.gov records should be consulted directly; those details were not consistently present in the extracted evidence snippets for all listed NCTs.

13. Prevention

Primary prevention of genetically determined EBS is not currently feasible, but genetic counseling and prenatal diagnosis are discussed in diagnostic guidelines: DNA-based prenatal diagnosis is technically feasible for EB subtypes once familial pathogenic variants are known, subject to national regulations and family preference. (Has et al., 2019-08) (has2019clinicalpracticeguidelines pages 1-2).

14. Other species / natural disease

A spontaneous KRT5 insertion variant has been reported as a novel nonhuman primate model of EBS in rhesus macaques (Macaca mulatta). Two stillborn homozygous animals had widespread epidermal loss, intraepidermal clefts above the basement membrane, absent cytokeratin-5 immunoreactivity in epidermis, and a 34-bp insertion in exon 5 of KRT5 (HGVS-like c.1087_1088ins...). (Johnson et al., Vet Pathol, 2020-02, https://doi.org/10.1177/0300985819900354) (johnson2020spontaneouskrt5gene pages 1-3).

15. Model organisms

The rhesus macaque KRT5 model above provides a spontaneous large-animal model with histologic and molecular features consistent with basal-layer cleavage. (johnson2020spontaneouskrt5gene pages 1-3). Additional model systems (mouse models; zebrafish transgenesis) were referenced in retrieved literature but were not extracted into evidence snippets sufficient for detailed annotation in this run. (bchetnia2024pathologicalmechanismsinvolved pages 1-2).

Evidence table (knowledge-base ready)

The following table consolidates key, evidence-supported facts.

Category Specific data points (with numbers) Best supporting citation IDs
Identifiers/Classification EBS is 1 of the 4 classical EB types; cleavage occurs within the basal layer of keratinocytes/intraepidermally. The 2020 consensus notes 7 genes associated with EBS. (has2020consensusreclassificationof pages 2-3, has2020consensusreclassificationof pages 1-2, bchetnia2024pathologicalmechanismsinvolved pages 1-2)
Core definition EBS is the most common EB subtype; one review cites ~70% of all EB, while a Dutch source cited in a patient-perspective review reports 45.7% of Dutch EB cases. (bardhan2020epidermolysisbullosa pages 1-2, stock2024thepatientsperspective pages 4-7)
Major subtypes Main clinical subtypes are localized, intermediate, and severe/generalized severe (historically Weber-Cockayne, Köebner, Dowling-Meara). In the German dataset, EBS subtypes were localized 39.5% and severe 14.7%; 33.4% lacked subclassification. In the China cohort, EBS cases were localized 17.5%, intermediate 35.0%, severe 27.2%. (has2020consensusreclassificationof pages 2-3, bchetnia2024pathologicalmechanismsinvolved pages 1-2, has2023epidemiologyofinherited pages 5-6, chen2023genotypeandphenotype pages 2-2)
Key genes Core genes: KRT5 and KRT14 are predominant; additional EBS genes include PLEC, KLHL24, DST, EXPH5, CD151. In a Middle Eastern cohort of 97 EBS patients, KRT5 accounted for 46% and KRT14 for 43% of EBS cases. In the China cohort, PLEC and KLHL24 were each mutated in 4 cases. (bchetnia2024pathologicalmechanismsinvolved pages 1-2, bergson2023clinicalandmolecular pages 1-2, chen2023genotypeandphenotype pages 3-3)
Inheritance Usually autosomal dominant; autosomal recessive forms also occur. In the German EB registry overall, inheritance counts were AD 222, AR 275, both 1, unavailable 53. In the China EB cohort, de novo mutations were high in EBS (63.8%) and mosaicism was reported in ~5.4% of dominant EBS. (has2020consensusreclassificationof pages 2-3, bchetnia2024pathologicalmechanismsinvolved pages 1-2, has2023epidemiologyofinherited pages 5-6, chen2023genotypeandphenotype pages 1-1)
Epidemiology Germany: overall EB incidence 45.09 per 1,000,000 live births (1 in 22,178); EBS incidence 14.93 per 1,000,000 live births (1:66,979). Germany prevalence estimates: overall EB 54.02/million; EBS 28.44/million. United States figures cited in reviews include incidence 8.2/million live births/year in newborn review, 11.1/million and prevalence 19.6/million in another review. (has2023epidemiologyofinherited pages 5-6, has2023epidemiologyofinherited pages 7-7, lucky2021diagnosisandcare pages 1-2, rosa2023stairwaystoadvanced pages 1-3)
Diagnostics Recommended neonatal workflow: skin biopsy for IFM plus blood for genetic testing in parallel. IFM can provide diagnosis within hours; biopsy sizes noted were 3-4 mm punch for IFM and 2-3 mm for EM. NGS-targeted EB panels typically have ~1 month turnaround. Genetic testing is always recommended; TEM is mainly for limited/inconclusive cases. (lucky2021diagnosisandcare pages 3-5, has2019clinicalpracticeguidelines pages 1-2, has2019clinicalpracticeguidelines pages 6-7, has2019clinicalpracticeguidelines pages 4-6)
Mechanisms Dominant KRT5/KRT14 mutations disrupt basal keratin intermediate filaments, causing keratin aggregates, ER stress, and pro-inflammatory signaling. Mechanistic pathways include IL-1β upregulation and JNK stress signaling; transcriptomic studies implicate inflammation, altered proliferation, differentiation, migration, and barrier homeostasis. (NCT02470689 chunk 1, bchetnia2024pathologicalmechanismsinvolved pages 1-2, bchetnia2024pathologicalmechanismsinvolved pages 8-10)
Treatments/Trials Diacerein: Phase 2 crossover trial NCT02470689 planned enrollment 50, ages 6-19, primary endpoint blister number at 4 weeks; prior pilot (n=5) reported blister reductions of -78% and -66% from baseline within 2 weeks. Long-term topical diacerein study NCT03389308 enrolled 51. TolaSure: Phase 1 NCT05062070 enrolled 6; Phase 2 NCT07027345 recruiting, enrollment 40. Sirolimus trial NCT03016715 enrolled 8. Botulinum toxin trials: NCT00936533 enrollment 40; NCT03453632 enrollment 25. Erythromycin Phase 3 NCT01340235 enrollment 8. (NCT02470689 chunk 1, bardhan2020epidermolysisbullosa pages 20-21, bchetnia2024pathologicalmechanismsinvolved pages 10-12, bchetnia2024pathologicalmechanismsinvolved pages 13-14)
QoL burden Global EBS survey: n=214, mean age 32.8 years. Reported blisters 93%, recurrent wounds 89%, pain 74%, chronic wounds 59%, itch 55%, difficulty walking 44%. Mean QOLEB score 14.7 (SD 7.5), indicating moderate impact; 12% required regular opiates. (so2022aglobalcrosssectional pages 10-12)
Models/other species Natural/experimental models include rhesus macaques with a 34-bp KRT5 insertion; 2 homozygous animals were stillborn with widespread epidermal loss, compared with 6 phenotypically normal heterozygotes. Other model systems referenced in retrieved literature include zebrafish transgenesis and mouse models of EBS-like disease. (so2022aglobalcrosssectional pages 1-2)

Table: This table compiles core disease knowledge-base facts for epidermolysis bullosa simplex, including classification, epidemiology, genetics, diagnostics, mechanisms, therapies, and patient burden. Each row is limited to information supported by gathered evidence and linked to the best available context IDs.

Limitations of this report (evidence availability)

  • Disease identifiers (OMIM/Orphanet/ICD/MeSH/MONDO): not retrievable from the evidence excerpts available in this run; therefore, this section is incomplete.
  • Differential diagnosis and comprehensive subtype-specific prognostic statistics: not fully extractable from the retrieved snippets.
  • ClinicalTrials.gov metadata for every EBS trial (status/enrollment/endpoints): only partially extractable from available excerpts; one EBS diacerein trial record (NCT02470689) was captured in detail. (NCT02470689 chunk 1).

References

  1. (has2020consensusreclassificationof pages 2-3): C. Has, J.W. Bauer, C. Bodemer, M.C. Bolling, L. Bruckner‐Tuderman, A. Diem, J.‐D. Fine, A. Heagerty, A. Hovnanian, M.P. Marinkovich, A.E. Martinez, J.A. McGrath, C. Moss, D.F. Murrell, F. Palisson, A. Schwieger‐Briel, E. Sprecher, K. Tamai, J. Uitto, D.T. Woodley, G. Zambruno, and J.E. Mellerio. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. British Journal of Dermatology, 183:614-627, Mar 2020. URL: https://doi.org/10.1111/bjd.18921, doi:10.1111/bjd.18921. This article has 905 citations and is from a highest quality peer-reviewed journal.

  2. (has2020consensusreclassificationof pages 1-2): C. Has, J.W. Bauer, C. Bodemer, M.C. Bolling, L. Bruckner‐Tuderman, A. Diem, J.‐D. Fine, A. Heagerty, A. Hovnanian, M.P. Marinkovich, A.E. Martinez, J.A. McGrath, C. Moss, D.F. Murrell, F. Palisson, A. Schwieger‐Briel, E. Sprecher, K. Tamai, J. Uitto, D.T. Woodley, G. Zambruno, and J.E. Mellerio. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. British Journal of Dermatology, 183:614-627, Mar 2020. URL: https://doi.org/10.1111/bjd.18921, doi:10.1111/bjd.18921. This article has 905 citations and is from a highest quality peer-reviewed journal.

  3. (bchetnia2024pathologicalmechanismsinvolved pages 1-2): Mbarka Bchetnia, Julie Powell, Catherine McCuaig, Anne-Marie Boucher-Lafleur, Charles Morin, Audrey Dupéré, and Catherine Laprise. Pathological mechanisms involved in epidermolysis bullosa simplex: current knowledge and therapeutic perspectives. International Journal of Molecular Sciences, 25:9495, Aug 2024. URL: https://doi.org/10.3390/ijms25179495, doi:10.3390/ijms25179495. This article has 11 citations.

  4. (has2019clinicalpracticeguidelines pages 1-2): C. Has, L. Liu, M.C. Bolling, A.V. Charlesworth, M. El Hachem, M.J. Escámez, I. Fuentes, S. Büchel, R. Hiremagalore, G. Pohla‐Gubo, P.C. Akker, K. Wertheim‐Tysarowska, and G. Zambruno. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. The British Journal of Dermatology, 182:574-592, Aug 2019. URL: https://doi.org/10.1111/bjd.18128, doi:10.1111/bjd.18128. This article has 186 citations.

  5. (has2023epidemiologyofinherited pages 7-7): Cristina Has, Moritz Hess, Waltraud Anemüller, Ulrike Blume‐Peytavi, Steffen Emmert, Regina Fölster‐Holst, Jorge Frank, Kathrin Giehl, Claudia Günther, Johanna Hammersen, Kathrin Hillmann, Bettina Höflein, Peter H. Hoeger, Alrun Hotz, Thuy Anh Mai, Vinzenz Oji, Holm Schneider, Kira Süßmuth, Iliana Tantcheva‐Póor, Frederieke Thielking, Birgit Zirn, Judith Fischer, and Antonia Reimer‐Taschenbrecker. Epidemiology of inherited epidermolysis bullosa in germany. Journal of the European Academy of Dermatology and Venereology, 37:402-410, Nov 2023. URL: https://doi.org/10.1111/jdv.18637, doi:10.1111/jdv.18637. This article has 56 citations and is from a domain leading peer-reviewed journal.

  6. (so2022aglobalcrosssectional pages 1-2): Jodi Y. So, Shivali Fulchand, Christine Y. Wong, Shufeng Li, Jaron Nazaroff, Emily S. Gorell, Mark P. de Souza, Dedee F. Murrell, Joyce M. Teng, Albert S. Chiou, and Jean Y. Tang. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet Journal of Rare Diseases, Jul 2022. URL: https://doi.org/10.1186/s13023-022-02433-3, doi:10.1186/s13023-022-02433-3. This article has 21 citations and is from a peer-reviewed journal.

  7. (NCT02470689 chunk 1): michal roll. Diacerin for the Treatment of Epidermolysis Bullosa Simplex. Tel-Aviv Sourasky Medical Center. 2015. ClinicalTrials.gov Identifier: NCT02470689

  8. (chen2023genotypeandphenotype pages 1-1): Fuying Chen, Ruoqu Wei, Dan Deng, Xue Zhang, Yu Cao, Chaolan Pan, Yumeng Wang, Qiaoyu Cao, Jianbo Wang, Ming Zeng, Linting Huang, Yan Gu, Zhirong Yao, and Ming Li. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from china. Journal of the European Academy of Dermatology and Venereology, 37:411-419, Nov 2023. URL: https://doi.org/10.1111/jdv.18692, doi:10.1111/jdv.18692. This article has 26 citations and is from a domain leading peer-reviewed journal.

  9. (has2023epidemiologyofinherited pages 5-6): Cristina Has, Moritz Hess, Waltraud Anemüller, Ulrike Blume‐Peytavi, Steffen Emmert, Regina Fölster‐Holst, Jorge Frank, Kathrin Giehl, Claudia Günther, Johanna Hammersen, Kathrin Hillmann, Bettina Höflein, Peter H. Hoeger, Alrun Hotz, Thuy Anh Mai, Vinzenz Oji, Holm Schneider, Kira Süßmuth, Iliana Tantcheva‐Póor, Frederieke Thielking, Birgit Zirn, Judith Fischer, and Antonia Reimer‐Taschenbrecker. Epidemiology of inherited epidermolysis bullosa in germany. Journal of the European Academy of Dermatology and Venereology, 37:402-410, Nov 2023. URL: https://doi.org/10.1111/jdv.18637, doi:10.1111/jdv.18637. This article has 56 citations and is from a domain leading peer-reviewed journal.

  10. (chen2023genotypeandphenotype pages 2-2): Fuying Chen, Ruoqu Wei, Dan Deng, Xue Zhang, Yu Cao, Chaolan Pan, Yumeng Wang, Qiaoyu Cao, Jianbo Wang, Ming Zeng, Linting Huang, Yan Gu, Zhirong Yao, and Ming Li. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from china. Journal of the European Academy of Dermatology and Venereology, 37:411-419, Nov 2023. URL: https://doi.org/10.1111/jdv.18692, doi:10.1111/jdv.18692. This article has 26 citations and is from a domain leading peer-reviewed journal.

  11. (so2022aglobalcrosssectional pages 6-8): Jodi Y. So, Shivali Fulchand, Christine Y. Wong, Shufeng Li, Jaron Nazaroff, Emily S. Gorell, Mark P. de Souza, Dedee F. Murrell, Joyce M. Teng, Albert S. Chiou, and Jean Y. Tang. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet Journal of Rare Diseases, Jul 2022. URL: https://doi.org/10.1186/s13023-022-02433-3, doi:10.1186/s13023-022-02433-3. This article has 21 citations and is from a peer-reviewed journal.

  12. (bergson2023clinicalandmolecular pages 1-2): Shir Bergson, Daniel Daniely, David Bomze, Janan Mohamad, Kiril Malovitski, Odile Meijers, Valeria Briskin, Ofer Bihari, Natalia Malchin, Shirli Israeli, Jacob Mashiah, Tzipora Falik‐Zaccai, Emily Avitan‐Hersh, Marina Eskin‐Schwartz, Stavit Allon‐Shalev, Ofer Sarig, Eli Sprecher, and Liat Samuelov. Clinical and molecular features in a cohort of middle eastern patients with epidermolysis bullosa. Pediatric Dermatology, 40:1021-1027, Oct 2023. URL: https://doi.org/10.1111/pde.15440, doi:10.1111/pde.15440. This article has 6 citations and is from a peer-reviewed journal.

  13. (chen2023genotypeandphenotype pages 3-3): Fuying Chen, Ruoqu Wei, Dan Deng, Xue Zhang, Yu Cao, Chaolan Pan, Yumeng Wang, Qiaoyu Cao, Jianbo Wang, Ming Zeng, Linting Huang, Yan Gu, Zhirong Yao, and Ming Li. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from china. Journal of the European Academy of Dermatology and Venereology, 37:411-419, Nov 2023. URL: https://doi.org/10.1111/jdv.18692, doi:10.1111/jdv.18692. This article has 26 citations and is from a domain leading peer-reviewed journal.

  14. (chen2023genotypeandphenotype pages 4-4): Fuying Chen, Ruoqu Wei, Dan Deng, Xue Zhang, Yu Cao, Chaolan Pan, Yumeng Wang, Qiaoyu Cao, Jianbo Wang, Ming Zeng, Linting Huang, Yan Gu, Zhirong Yao, and Ming Li. Genotype and phenotype correlations in 441 patients with epidermolysis bullosa from china. Journal of the European Academy of Dermatology and Venereology, 37:411-419, Nov 2023. URL: https://doi.org/10.1111/jdv.18692, doi:10.1111/jdv.18692. This article has 26 citations and is from a domain leading peer-reviewed journal.

  15. (rosa2023stairwaystoadvanced pages 1-3): Laura De Rosa, Elena Enzo, Michele Palamenghi, Laura Sercia, and Michele De Luca. Stairways to advanced therapies for epidermolysis bullosa. Cold Spring Harbor perspectives in biology, 15:a041229, Sep 2023. URL: https://doi.org/10.1101/cshperspect.a041229, doi:10.1101/cshperspect.a041229. This article has 14 citations and is from a peer-reviewed journal.

  16. (has2019clinicalpracticeguidelines pages 6-7): C. Has, L. Liu, M.C. Bolling, A.V. Charlesworth, M. El Hachem, M.J. Escámez, I. Fuentes, S. Büchel, R. Hiremagalore, G. Pohla‐Gubo, P.C. Akker, K. Wertheim‐Tysarowska, and G. Zambruno. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. The British Journal of Dermatology, 182:574-592, Aug 2019. URL: https://doi.org/10.1111/bjd.18128, doi:10.1111/bjd.18128. This article has 186 citations.

  17. (lucky2021diagnosisandcare pages 3-5): Anne W. Lucky, Jean Whalen, Susan Rowe, Kalyani S. Marathe, and Emily Gorell. Diagnosis and care of the newborn with epidermolysis bullosa. NeoReviews, 22 7:e438-e451, Jul 2021. URL: https://doi.org/10.1542/neo.22-7-e438, doi:10.1542/neo.22-7-e438. This article has 44 citations.

  18. (has2019clinicalpracticeguidelines pages 10-11): C. Has, L. Liu, M.C. Bolling, A.V. Charlesworth, M. El Hachem, M.J. Escámez, I. Fuentes, S. Büchel, R. Hiremagalore, G. Pohla‐Gubo, P.C. Akker, K. Wertheim‐Tysarowska, and G. Zambruno. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. The British Journal of Dermatology, 182:574-592, Aug 2019. URL: https://doi.org/10.1111/bjd.18128, doi:10.1111/bjd.18128. This article has 186 citations.

  19. (has2023epidemiologyofinherited pages 7-8): Cristina Has, Moritz Hess, Waltraud Anemüller, Ulrike Blume‐Peytavi, Steffen Emmert, Regina Fölster‐Holst, Jorge Frank, Kathrin Giehl, Claudia Günther, Johanna Hammersen, Kathrin Hillmann, Bettina Höflein, Peter H. Hoeger, Alrun Hotz, Thuy Anh Mai, Vinzenz Oji, Holm Schneider, Kira Süßmuth, Iliana Tantcheva‐Póor, Frederieke Thielking, Birgit Zirn, Judith Fischer, and Antonia Reimer‐Taschenbrecker. Epidemiology of inherited epidermolysis bullosa in germany. Journal of the European Academy of Dermatology and Venereology, 37:402-410, Nov 2023. URL: https://doi.org/10.1111/jdv.18637, doi:10.1111/jdv.18637. This article has 56 citations and is from a domain leading peer-reviewed journal.

  20. (bardhan2020epidermolysisbullosa pages 1-2): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  21. (bchetnia2024pathologicalmechanismsinvolved pages 10-12): Mbarka Bchetnia, Julie Powell, Catherine McCuaig, Anne-Marie Boucher-Lafleur, Charles Morin, Audrey Dupéré, and Catherine Laprise. Pathological mechanisms involved in epidermolysis bullosa simplex: current knowledge and therapeutic perspectives. International Journal of Molecular Sciences, 25:9495, Aug 2024. URL: https://doi.org/10.3390/ijms25179495, doi:10.3390/ijms25179495. This article has 11 citations.

  22. (bchetnia2024pathologicalmechanismsinvolved pages 13-14): Mbarka Bchetnia, Julie Powell, Catherine McCuaig, Anne-Marie Boucher-Lafleur, Charles Morin, Audrey Dupéré, and Catherine Laprise. Pathological mechanisms involved in epidermolysis bullosa simplex: current knowledge and therapeutic perspectives. International Journal of Molecular Sciences, 25:9495, Aug 2024. URL: https://doi.org/10.3390/ijms25179495, doi:10.3390/ijms25179495. This article has 11 citations.

  23. (bardhan2020epidermolysisbullosa pages 20-21): Ajoy Bardhan, Leena Bruckner-Tuderman, Iain L. C. Chapple, Jo-David Fine, Natasha Harper, Cristina Has, Thomas M. Magin, M. Peter Marinkovich, John F. Marshall, John A. McGrath, Jemima E. Mellerio, Rex Polson, and Adrian H. Heagerty. Epidermolysis bullosa. Nature Reviews Disease Primers, 6:1-27, Sep 2020. URL: https://doi.org/10.1038/s41572-020-0210-0, doi:10.1038/s41572-020-0210-0. This article has 551 citations.

  24. (johnson2020spontaneouskrt5gene pages 1-3): Amanda L. Johnson, Samuel M. Peterson, Margaret M. L. Terry, Betsy Ferguson, Lois M. Colgin, and Anne D. Lewis. Spontaneous krt5 gene mutation in rhesus macaques (macaca mulatta): a novel nonhuman primate model of epidermolysis bullosa simplex. Veterinary Pathology, 57:344-348, Feb 2020. URL: https://doi.org/10.1177/0300985819900354, doi:10.1177/0300985819900354. This article has 8 citations and is from a domain leading peer-reviewed journal.

  25. (stock2024thepatientsperspective pages 4-7): C Stock. The patient's perspective: a review on epidermolysis bullosa patients' needs as input towards harmonization of outcomes. Unknown journal, 2024.

  26. (lucky2021diagnosisandcare pages 1-2): Anne W. Lucky, Jean Whalen, Susan Rowe, Kalyani S. Marathe, and Emily Gorell. Diagnosis and care of the newborn with epidermolysis bullosa. NeoReviews, 22 7:e438-e451, Jul 2021. URL: https://doi.org/10.1542/neo.22-7-e438, doi:10.1542/neo.22-7-e438. This article has 44 citations.

  27. (has2019clinicalpracticeguidelines pages 4-6): C. Has, L. Liu, M.C. Bolling, A.V. Charlesworth, M. El Hachem, M.J. Escámez, I. Fuentes, S. Büchel, R. Hiremagalore, G. Pohla‐Gubo, P.C. Akker, K. Wertheim‐Tysarowska, and G. Zambruno. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. The British Journal of Dermatology, 182:574-592, Aug 2019. URL: https://doi.org/10.1111/bjd.18128, doi:10.1111/bjd.18128. This article has 186 citations.

  28. (bchetnia2024pathologicalmechanismsinvolved pages 8-10): Mbarka Bchetnia, Julie Powell, Catherine McCuaig, Anne-Marie Boucher-Lafleur, Charles Morin, Audrey Dupéré, and Catherine Laprise. Pathological mechanisms involved in epidermolysis bullosa simplex: current knowledge and therapeutic perspectives. International Journal of Molecular Sciences, 25:9495, Aug 2024. URL: https://doi.org/10.3390/ijms25179495, doi:10.3390/ijms25179495. This article has 11 citations.

  29. (so2022aglobalcrosssectional pages 10-12): Jodi Y. So, Shivali Fulchand, Christine Y. Wong, Shufeng Li, Jaron Nazaroff, Emily S. Gorell, Mark P. de Souza, Dedee F. Murrell, Joyce M. Teng, Albert S. Chiou, and Jean Y. Tang. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex. Orphanet Journal of Rare Diseases, Jul 2022. URL: https://doi.org/10.1186/s13023-022-02433-3, doi:10.1186/s13023-022-02433-3. This article has 21 citations and is from a peer-reviewed journal.